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Abstract 
Calcineurin  is  both  necessary  and  sufficient  to  induce  cardiac  hypertrophy,  an  
independent  risk  factor  for  arrhythmia,  dilated  cardiomyopathy,  heart  failure,  and  
sudden  cardiac  death.    However,  current  knowledge  of  the  downstream  effectors  of  
calcineurin  is  limited.    My  study  utilizes  Drosophila  melanogaster  to  1)  establish  a  reliable  
model  for  discovering  novel  modifiers  of  calcineurin-­‐‑induced  cardiomyopathy;  and  2)  
discover  and  characterize  novel  modifiers  of  calcineurin-­‐‑induced  cardiomyopathy.  
In  this  study,  I  generated  sensitized  Drosophila  lines  expressing  constitutively  
active  calcineurin  (CanAact)  that  was  either  fused  to  yellow  fluorescent  protein  (YFP)  or  a  
Flag  epitope  (Flag-­‐‑tagged)  specifically  in  the  heart  using  the  cardiac-­‐‑specific  tinC  driver  
(tinC-­‐‑CanAact).    These  sensitized  lines  displayed  significant  cardiac  enlargement  as  
assayed  via  optical  coherence  tomography  (OCT),  histology,  and  confocal  microscopy.    
The  feasibility  of  this  method  was  established  by  testing  Drosophila  expressing  deficiency  
of  a  known  calcineurin  modifier,  Mef2.      
Employing  a  targeted  deficiency  screen  informed  by  calcineurin  modifier  screens  
in  the  eye  and  mesoderm,  Galactokinase  (Galk)  was  discovered  as  a  novel  modifier  of  
calcineurin-­‐‑induced  cardiomyopathy  in  the  fly  through  1)  genetic  deficiencies,  
transposable  elements,  and  RNAi  disrupting  Galk  expression  rescued  tinC-­‐‑CanAact-­‐‑
induced  cardiomyopathy;  and  2)  transposable  element  in  Galk  rescued  tinC-­‐‑CanAact-­‐‑
induced  decreased  life  span.    Further  characterization  identified  that  the  genetic  
     v  
disruption  of  Galk  rescued  CanAact-­‐‑induced  phenotypes  driven  in  the  posterior  wing,  but  
not  ectodermaly,  mesodermaly,  or  ubiquitously  driven  phenotypes.    In  a  separate  
region,  genetic  disruption  of  the  galactoside-­‐‑binding  lectin,  galectin,  was  also  found  to  
rescue  tinC-­‐‑CanAact-­‐‑induced  cardiac  enlargement.  
Together,  these  results  characterize  tinC-­‐‑CanAact-­‐‑induced  cardiac  enlargement  in  
the  fly,  establish  that  the  tinC-­‐‑CanAact  sensitized  line  is  a  reliable  model  for  discovering  
novel  calcineurin  regulators  and  suggest  that  galactokinase  and  galectin-­‐‑regulated  
glycosylation  is  important  for  calcineurin-­‐‑induced  cardiomyopathy.    These  results  have  
the  potential  to  provide  insight  into  new  treatments  for  cardiac  hypertrophy.  
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Chapter 1. Background and Introduction 
My  study  aims  to  1)  establish  a  reliable  model  for  discovering  novel  modifiers  of  
calcineurin-­‐‑induced  cardiomyopathy  using  Drosophila  melanogaster;  2)  discover  and  
characterize  novel  modifiers  of  calcineurin-­‐‑induced  cardiomyopathy.    This  research  
utilizes  an  efficient  Drosophila  model  and  provides  insight  into  treating  the  detrimental  
effects  of  calcineurin  and  cardiac  hypertrophy.  
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1.1 Calcineurin: structure and function 
Calcineurin  acts  as  a  calcium/calmodulin-­‐‑dependent  protein  phosphatase  that  
consists  of  two  subunits:  a  large  CanA  subunit  (60  kD),  and  a  small  CanB  subunit  (19  
kD).    In  the  mouse,  there  are  three  CanA  genes  (Ppp3ca,  Ppp3cb,  and  Ppp3cc)  and  two  
CanB  genes  (Ppp3r1  and  Ppp3r2),  only  Ppp3ca,  Ppp3cb  and  Ppp3r1  are  expressed  in  the  
heart;  in  the  fly,  there  are  three  CanA  genes  (CanA1,  CanA-­‐‑14F,  and  Pp2B-­‐‑14D)  and  two  
CanB  genes  (CanB  and  CanB2),  CanA1,  CanA-­‐‑14F,  and  CanB  have  low  expression  while  
Pp2B-­‐‑14D  and  CanB2  have  moderate  to  high  expression  in  the  fly  heart.  (NCBI  Gene:  
http://www.ncbi.nlm.nih.gov/gene)    The  coding  sequences  for  calcineurin  subunits  are  
highly  conserved  between  mammals  and  flies:  73-­‐‑78%  identical  for  CanA  [1,  2]  and  88%  
identical  for  CanB  [3-­‐‑5]  with  the  catalytic  regions  close  to  completely  conserved  between  
species.      
The  large  CanA  subunit  has  phosphatase  activity  and  consists  of  several  
domains:  the  catalytic  domain,  which  regulates  protein  dephosphorylation  [6],  the  CanB  
binding  domain  [7],  the  calcium/calmodulin  binding  domain,  and  the  autoinhibitory  
domain  [8].    In  the  inactive  state,  the  autoinhibitory  domain  inhibits  the  catalytic  
domain.    Binding  of  calcium/calmodulin  activates  calcineurin  by  alleviating  this  
autoinhibition.    A  constitutively  active  calcineurin  (CanAact)  is  generated  by  eliminating  
the  autoinhibitory  domain,  and  has  been  used  in  previous  studies  to  investigate  
calcineurin  signaling  [9-­‐‑11].    Expression  of  constitutively  active  calcineurin  (CanAact)  has  
     3  
been  found  to  induce  cardiac  hypertrophy  [9],  skeletal  muscle  hypertrophy  [12,  13]  and  
slow  twitch  skeletal  muscle  specification  [14,  15].    The  smaller  subunit  (CanB)  is  
constitutively  bound  to  CanA  and  is  required  for  maintaining  calcineurin  expression  
[16-­‐‑18].    Deficiency  of  CanB  results  in  significant  cardiomyopathy,  including  impaired  
cardiomyocyte  growth,  impaired  contractility,  and  lethality  after  birth  [19,  20].    In  
addition  to  cardiac  and  skeletal  muscle  hypertrophy,  calcineurin  is  involved  in  many  
diverse  processes:  T  cell  activation  [21],  chondrogenesis  [22],  synaptic  plasticity  [23,  24],  
apoptosis  [25],  and  cardiovascular  development  [26,  27].  
  
1.1.1 NFAT as a modifier of calcineurin-induced cardiomyopathy 
NFAT  (Nuclear  factor  of  activated  T-­‐‑cells)  is  well  characterized  as  a  major  
downstream  effector  of  calcineurin  signaling,  and  is  both  necessary  and  sufficient  to  
induce  cardiac  hypertrophy  [5,  28].    There  are  5  vertebrate  NFAT  genes,  NFATc1-­‐‑5,  
while  only  the  NFATc5  orthologue,  not  regulated  by  calcineurin  [29,  30],  exists  in  
Drosophila.    NFATc1-­‐‑4  consist  of  several  domains:  the  DNA  binding  domain  which  is  
highly  conserved  between  the  NFAT  proteins,  the  NFAT  homology  region  which  binds  
calcineurin  and  is  absent  from  NFATc5,  the  N-­‐‑terminus  transcriptional  activation  
domain,  and  the  C-­‐‑terminus  transcriptional  activation  domain  which  are  largely  
variable  between  the  NFAT  genes  [31].    The  different  NFAT  genes  are  found  to  be  
expressed  in  most  tissues  with  distinct  temporal  and  spatial  patterns  [31].    
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NFAT-­‐‑induced  transcription  is  regulated  at  multiple  levels:  dephosphorylation  
of  NFAT  by  calcineurin  induces  translocation  into  the  nucleus  and  increases  DNA  
binding  affinity  [32];  phosphorylation  of  NFAT  by  glycogen  synthase  kinase  (GSK-­‐‑3),  
protein  kinase  A  (PKA),  p38,  JNK,  and  caseine  kinase  deactivates  NFAT,  facilitating  
cytoplasmic  localization  [33-­‐‑36];  and  NFAT  induces  transcription  in  cooperation  with  
other  transcription  factors  including  AP-­‐‑1,  Mef2,  and  GATA4  [9,  14,  37].    NFAT  
regulates  the  expression  of  many  genes,  including  interleukin-­‐‑2,3,4  (IL-­‐‑2,3,4),  
cyclooxygenase-­‐‑2,  (Cox-­‐‑2),  tumor  necrosis  factor-­‐‑α  (TNF-­‐‑α),  atrial  natriuretic  factor  
(ANF),  b-­‐‑type  natriuretic  peptide  (BNP),  myosin  heavy  chain  (MHC),  MCIP-­‐‑1,  
endothelin  1  (ET-­‐‑1),  and  troponin  I,  many  of  which  are  up-­‐‑regulated  in  cardiac  
hypertrophy  [9,  38-­‐‑43].    This  suggests  that  NFAT  induces  cardiac  hypertrophy  by  
activating  gene  expression.    In  addition,  expressing  constitutively  active  NFAT  in  the  
heart  was  sufficient  to  induce  concentric  cardiac  hypertrophy,  suggesting  that  NFAT  is  a  
major  pathway  in  calcineurin-­‐‑induced  cardiomyopathy  [9].  
Calcineurin  regulation  of  NFAT  was  first  characterized  in  T-­‐‑cell  activation  [21]  
and  later  discovered  to  regulate  many  processes  including  chondrogenesis  [22],  thymic  
development  [44],  cardiac  morphogenesis  [26],  and  vascular  development  [27].    
Calcineurin-­‐‑regulated  NFAT  is  not  present  in  the  fly.    However,  a  study  used  Drosophila  
S2  cells  to  identify  a  novel  regulator  of  calcineurin-­‐‑induced  NFAT  translocation  [45],  
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indicating  that  the  molecules  involved  in  regulating  NFAT  downstream  of  calcineurin  
are  present  in  the  fly.  
  
1.1.2 Mef2 as a modifier of calcineurin-induced cardiomyopathy 
Myocyte  enhancer  factor  (Mef2)  is  a  well-­‐‑known  NFAT-­‐‑independent  pathway  
that  has  been  implicated  in  calcineurin-­‐‑mediated  cardiac  hypertrophy  [15,  46].    In  
vertebrates,  there  are  four  Mef2  genes:  Mef2a,  Mef2b,  Mef2c,  and  Mef2d.    There  is  only  one  
Mef2  family  member  in  the  fly.    Each  Mef2  consists  of  several  subdomains:  a  DNA  
binding  and  activation  domain  (including  a  MADS  box  domain  and  a  Mef2  domain),  
and  a  transcriptional  activation  domain.    The  MADS  domain  is  conserved  90-­‐‑95%  
between  vertebrate  and  Drosophila  Mef2;  the  Mef2  domain  is  conserved  68-­‐‑87%  between  
vertebrate  and  Drosophila  Mef2;  the  transcriptional  activation  domain  is  more  variable,  
and  is  only  conserved  6-­‐‑16%  between  the  vertebrate  and  Drosophila  Mef2  [47].    Drosophila  
Mef2  is  most  highly  conserved  with  mammalian  Mef2c.    The  expression  pattern  of  the  
different  vertebrate  Mef2  isoforms  is  distinct  but  overlapping,  both  spatially  and  
temporally.    Mef2c  is  the  first  transcript  to  be  expressed,  starting  embryonic  day  7.5  in  
the  heart  in  mesothelial  cells  in  the  anterior  heart  while  Mef2a  and  Mef2d  are  expressed  
highly  after  day  8.5  in  the  heart  [47,  48].    Somatic  precursors  and  limb  buds  also  express  
Mef2  genes  starting  with  Mef2c  expression  at  day  8.5  and  Mef2a  and  Mef2d  at  
embryonic  day  9.5.    These  differences  suggest  differing  functionality  for  each  of  the  Mef2  
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genes.    Drosophila  Mef2  is  expressed  throughout  the  mesoderm  since  gastrulation  and  
maintains  expression  in  all  precursors  and  differentiated  muscle  [49].    Mef2  is  regulated  
through  many  diverse  mechanisms:  Mef2  functions  as  either  homo-­‐‑  or  heterodimers  [50-­‐‑
53],  is  repressed  by  histone  deacetylases  (HDACs)  [54,  55],  recruits  activator  proteins  
such  as  mastermind-­‐‑like  (MAML)  and  ERK5  [56,  57],  and  post-­‐‑translational  modification  
through  phosphorylation  [58,  59].  
Calcineurin-­‐‑mediated  Mef2  signaling  has  been  investigated  in  many  studies.    
Cardiac  calcineurin  expression  has  been  shown  to  activate  Mef2  reporter  activity  [60].    
The  expression  of  a  dominant-­‐‑negative  Mef2  inhibited  CanAact-­‐‑induced  cardiac  
enlargement  and  overexpressing  Mef2  caused  cardiac  chamber  dilation  [61].    In  skeletal  
muscle,  calcineurin  activates  Mef2  with  exercise  [46,  62].    Mechanistically,  calcineurin  
was  found  to  co-­‐‑immunoprecipitate  with  Mef2  and  induce  activation  of  Mef2  through  
dephosphorylation  [46].    The  binding  of  Mef2  and  calcineurin  is  mediated  by  the  
scaffolding  protein  mAKAP  [63].  
Although  no  studies  have  examined  the  role  of  Mef2  downstream  of  calcineurin  
in  the  Drosophila  heart,  preliminary  studies  using  Drosophila  flight  muscle  showed  that  
mutation  of  Mef2  modified  lethality  with  mesodermally-­‐‑expressed  constitutively  active  
calcineurin  [11].  Mutating  Mef2  in  Drosophila  results  in  the  failure  to  induce  myosin  
heavy  chain  expression  and  form  differentiated  muscle  of  all  lineages,  including  cardiac,  
somatic,  and  visceral  [64-­‐‑66].    Both  null-­‐‑mutations  in  Mef2  and  overexpressing  Mef2  
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mesodermally  result  in  late  embryonic  lethality  [64,  67].    Similarly,  the  phenotype  
observed  in  flies  overexpressing  mesodermal  constitutively  active  calcineurin  is  late  
pupal  stage  lethal  with  the  inability  for  flight  muscle  differentiation  and  myosin  heavy  
chain  expression  [11]  and  CanB  null  mutation  also  results  in  late  pupal  lethality  [10,  11].    
This  is  consistent  with  the  notion  that  Mef2  acts  downstream  of  calcineurin  and  suggests  
that  appropriate  regulation  of  Mef2  by  calcineurin  is  required  for  normal  muscle  
differentiation.  
  
1.1.3 Other modifiers of calcineurin-induced cardiomyopathy  
In  addition  to  the  above  mentioned  effectors  inducing  cardiac  hypertrophy  
downstream  of  calcineurin,  many  additional  proteins  have  been  discovered  to  modify  
calcineurin-­‐‑induced  cardiac  hypertrophy  and  signaling.      
The  myocyte-­‐‑enriched  calcineurin-­‐‑interacting  protein-­‐‑1  (MCIP1)  [68],  calcineurin  
inhibitor  protein  (Cain)  [69],  and  AKAP79  [70]  inhibit  calcineurin  by  direct  binding  and  
modify  calcineurin-­‐‑induced  cardiac  hypertrophy  [71,  72].    There  are  no  Drosophila  
homologues  of  MCIP1,  cain,  or  AKAP79.      
To  date,  no  prior  studies  have  focused  on  modifiers  of  calcineurin-­‐‑induced  
cardiomyopathy  in  the  fly.    Instead,  screens  in  the  fly  have  focused  on  changes  in  the  fly  
eye  or  lethality  related  to  mesodermal  calcineurin  expression.    One  screen  for  modifiers  
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of  calcineurin  in  the  eye  discovered  sprouty,  CanB2,  and  Mef2  as  modifiers  of  calcineurin-­‐‑
induced  rough  eye  [10].    Sprouty  is  a  negative  regulator  of  EGFR  signaling.      
An  additional  independent  suppressor  screen  of  mesodermally  expressed  
calcineurin-­‐‑induced  lethality  was  performed  and  identified  CanB2  and  Mef2  as  modifiers  
of  calcineurin-­‐‑induced  lethality  [11].    These  prior  investigations  underscore  the  
importance  of  Mef2  in  calcineurin  signaling  and  highlight  the  observation  that  other  as-­‐‑
yet-­‐‑unidentified  modifiers  exist  that  potentially  impact  calcineurin  signaling.  
  
1.2 Calcineurin and cardiomyopathy 
Numerous  studies  have  concluded  that  calcineurin  is  both  necessary  and  
sufficient  to  induce  cardiac  hypertrophy  [9,  72-­‐‑76].    Expressing  constitutively  active  
calcineurin  (CanAact)  in  the  mouse  heart  results  in  a  cardiac  hypertrophy  phenotype  
characterized  by  a  thicker  heart  wall  and  an  enlarged  cardiac  chamber,  which  
progressed  to  heart  failure  and  sudden  premature  death  [9].    Inhibiting  calcineurin  with  
the  calcineurin  inhibitors  cyclosporin  A  or  FK506  attenuated  cardiomyopathy  in  mice  
with  mutations  in  tropomodulin,  myosin  light  chain-­‐‑2,  or  fetal  β-­‐‑tropomyosin  (genes  
associated  with  familial  cardiac  hypertrophy)  in  the  heart.    In  the  same  study,  FK506  
calcineurin  inhibition  was  also  found  to  attenuate  cardiac  hypertrophy  caused  by  
pressure  overload  in  rats  [76].    Calcineurin  mRNA  and  protein  levels  are  increased  in  rat  
cardiomyocytes  upon  stimulation  with  hypertrophic  agents  such  as  angiotensin  II,  
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phenylephrine,  and  1%  fetal  bovine  serum.    Genetic  inhibition  by  expressing  the  
calcineurin  inhibition  proteins  Cain  and  AKAP79  with  adenovirus  attenuated  
angiotensin  II,  phenylephrine,  and  1%  fetal  bovine  serum-­‐‑induced  hypertrophy  in  
cultured  rat  cardiomyocytes  [72].    Calcineurin  null  mice  have  decreased  heart  size  and  
do  not  display  cardiac  hypertrophy  after  provocation  by  pressure  overload,  or  
angiotensin  II  or  isoproterynol  stimulation  [73].    Activated  calmodulin-­‐‑bound  
calcineurin  is  upregulated  4  fold  in  failing  human  heart  tissue  [75].    Angiotensin  II-­‐‑
induced  cardiac  hypertrophy  in  rats  was  suppressed  by  cyclosporine  (CsA),  a  
calcineurin  inhibitor  [74,  77].  
To  summarize  the  above  findings,  calcineurin  has  been  proven  to  be  important  
for  cardiomyopathy  on  multiple  levels:  1)  expressing  constitutively  active  calcineurin  
(CanAact)  in  the  heart  causes  cardiac  hypertrophy;  2)  calcineurin  activity  is  increased  
with  hypertrophic  stimulation;  3)  inhibiting  calcineurin  genetically  and  
pharmacologically  attenuates  genetic  or  induced  cardiac  hypertrophy.  
Current  knowledge  of  calcineurin  signaling  leading  to  cardiac  hypertrophy  is  
summarized  in  Figure  1.    Calcineurin  signaling  in  mammals  involves  calcineurin-­‐‑
dependent  dephosphorylation  of  nuclear  factor  of  activated  T  cells  (NFAT)  transcription  
factors  [9,  78].    The  calcineurin/NFAT  pathway  was  initially  discovered  in  T-­‐‑cell  
activation  and  is  the  most  well  studied  pathway  downstream  of  calcineurin  activation  
[79].    In  contrast,  Drosophila  do  not  contain  calcineurin-­‐‑regulated  isoforms  of  NFAT  and  
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use  NFAT-­‐‑independent  pathways  [80].    As  such,  whether  calcineurin  will  induce  a  




Figure  1:  Known  pathways  regulated  by  calcineurin  signaling.  
Currently  known  signaling  pathways  related  to  calcineurin  signaling.    With  
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(ET-­‐‑1),  phenylephrine  (PE),  or  mechanical  stress,  intracellular  calcium  concentration  is  
increased,  triggering  the  activation  of  the  calcineurin  complex  by  calcium/calmodulin  
(CaM)  and  binding  with  the  CanB  subunit.    Activated  calcineurin  then  
dephosphorylates  NFAT,  leading  to  nuclear  translocation  and  downstream  hypertrophic  
gene  transcription.    Another  known  pathway  downstream  of  calcineurin  activation  is  
dephosphorylation  and  activation  of  Mef2,  leading  to  activation  of  downstream  
hypertrophic  signaling.    Adapted  from  [81].  
  
  
In  contrast  to  the  above-­‐‑mentioned  pathological  cardiac  hypertrophy,  cardiac  
hypertrophy  stimulated  by  exercise  is  physiological,  is  not  typically  associated  with  
abnormal  cardiac  function,  and  does  not  stimulate  calcineurin/NFAT  signaling  [82].    
These  findings  further  support  that  calcineurin  negatively  impacts  cardiac  function  and  
understanding  calcineurin  downstream  signaling  factors  is  important  for  our  
understanding  of  cardiac  disease.    In  addition,  current  inhibitors  (cyclosporin  A  and  
FK501)  of  calcineurin  exert  side  effects  with  immunosuppression,  nephrotoxicity,  and  
off-­‐‑target  effects,  further  demanding  the  need  for  insight  into  calcineurin  signaling  for  
treatment  of  cardiac  hypertrophy.  
     12  
1.3 Cardiac hypertrophy: progression and signaling 
Cardiovascular  disease  is  the  leading  cause  of  mortality  in  the  United  States  of  
America.    Pathological  cardiac  hypertrophy  is  a  response  initiated  by  multiple  factors  
including  stress  (neuroendocrine  factors),  hypertension  (pressure  overload),  valve  
dysfunction  (volume  overload),  and  familial  mutations  in  sarcomeric  or  calcium  
handling  genes.    Initially,  this  response  compensates  for  cardiac  function  by  increasing  
cardiac  muscle.    However,  prolonged  cardiac  hypertrophy  is  a  known  independent  risk  
factor  for  arrhythmia,  dilated  cardiomyopathy,  heart  failure,  and  sudden  death  [83-­‐‑86].    
These  results  indicate  that  intervention  and  treatment  of  cardiac  hypertrophy  is  an  
important  aspect  of  treating  cardiac  disease.  
Pathological  cardiac  hypertrophy  shows  many  morphological  and  biochemical  
changes.    Based  on  morphology  of  the  cardiac  wall,  two  types  of  cardiac  hypertrophy  
are  characterized:  1)  concentric  hypertrophy,  where  sarcomeres  are  added  in  parallel  
and  cause  the  cardiac  wall  to  thicken  [87],  and  2)  eccentric  hypertrophy,  where  
sarcomeres  added  in  series  induce  an  increase  in  the  radius  of  the  wall  [88,  89].    
Biochemically,  many  changes  to  protein  and  gene  expression  have  been  shown.    The  
adult  onset  of  a  fetal  gene  program  is  elicited:  atrial  natriuretic  factor  (ANF)  is  induced  
in  both  pressure-­‐‑overload-­‐‑induced  concentric  hypertrophy  and  volume-­‐‑overload-­‐‑
induced  eccentric  hypertrophy  while  skeletal  muscle  α-­‐‑actin  and  β-­‐‑myosin  heavy  chain  
are  induced  with  pressure-­‐‑overload  [90].    Expression  of  sarcoplasmic  (endoplasmic)  
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reticulum  calcium-­‐‑ATPase  2A  (SERCA)  is  decreased,  which  leads  to  abnormal  calcium  
regulation  and  contractility  of  the  heart.    In  addition  to  an  increase  in  cardiomyocyte  
size,  fibrosis,  arrhythmia,  and  myofibrillar  disarray  are  also  characteristics  of  
pathological  cardiac  hypertrophy.  
In  addition  to  the  aforementioned  calcineurin-­‐‑related  pathways,  several  branches  
of  signaling  pathways  have  been  found  in  induced  cardiac  hypertrophy.    These  
pathways  form  a  complex  network  of  regulation  involving  crosstalk  at  multiple  points  
[91].    One  major  pathway  regulating  cardiac  hypertrophy  involves  neuroendocrine  
factors  such  as  endothelin  (ET-­‐‑1),  angiotensin  II  (AngII),  and  catecholamines  binding  to  
G  protein  coupled  receptors  (GPCRs  associated  with  Gαq/11)  which  signal  through  
phospholipase  C  (PLC)  to  increase  calcium  concentration,  activation  of  protein  kinase  C  
(PKC),  calcium/calmodulin  activated  kinase  (CaMK),  export  of  histone  deacetylases  
(HDAC),  and  activation  of  Mef2  [92,  93].    The  increase  in  calcium  also  activates  
calcineurin  through  binding  of  calcium/calmodulin  [94].      
Another  major  pathway  in  cardiac  hypertrophy  is  the  mitogen-­‐‑activated  protein  
kinase  (MAPK)  signaling  pathway:  GPCRs  (ET-­‐‑1,  AngII),  receptor  tyrosine  kinases  (IGF-­‐‑
1,  FGF  receptors),  receptor  serine/threonine  kinases  (TGFβ),  reactive  oxygen  species  
(ROS),  and  mechanical  stretch  activate  the  MAPK  signaling  cascade,  signaling  to  ERK,  
JNK,  or  p38-­‐‑MAPK  [91,  95].    Interestingly,  expressing  activated  MEK1,  which  directly  
activates  ERK,  induced  a  compensated  cardiac  hypertrophy  that  is  not  associated  with  
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heart  failure  [96],  while  overexpressing  a  constitutively  active  form  of  the  upstream  
activator  Ras,  which  activates  ERK,  JNK,  and  PI3K  [97],  induced  a  pathological  
phenotype  [98].    Several  studies  have  also  indicated  that  ERK  plays  a  protective  role  in  
inhibiting  apoptosis  [99,  100]  while  also  activating  NFAT  gene  expression  [101].    The  
distinct  roles  of  these  pathways  and  their  involvement  in  eccentric  vs.  concentric  
hypertrophy  are  currently  unclear.    Recent  studies  in  transgenic  mice  suggest  that  
activating  the  MEK1/ERK1/2  pathway  promotes  concentric  hypertrophy  [96]  while  
MEK5/ERK5  activation  promotes  eccentric  hypertrophy  [102].    To  add  to  the  complexity  
of  signals  underlying  cardiac  hypertrophy,  a  study  examining  different  mouse  models  
that  display  cardiac  hypertrophy  (further  discussed  in  the  next  section)  discovered  that  
the  upregulated  genes  did  not  completely  overlap.    In  this  study,  gene  upregulation  was  
analyzed  for  mice  expressing  protein  kinase  C-­‐‑ε  activating  peptide  (ΨεRACK),  
calsequestrin  (CSQ),  calcineurin,  and  Gαq  using  microarray.    These  results  indicate  that  
a  similar  phenotype  of  cardiac  hypertrophy  can  be  elicited  from  distinct  sets  of  gene  
expression  [103].    These  studies  suggest  that  pathological  cardiac  hypertrophy  results  
from  a  balance  of  multiple  intracellular  signaling  pathways  that  remain  to  be  elucidated.  
Hypertrophy  of  the  heart  can  also  be  triggered  in  the  form  of  genetically  
inherited  disease,  familial  hypertrophic  cardiomyopathy.    Familial  hypertrophic  
cardiomyopathy  manifests  as  thickening  of  the  cardiac  wall,  myofibrillar  disarray,  and  
fibrosis  [104].    It  is  characterized  as  a  monogenic  Mendelian-­‐‑inherited  disease  resulting  
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from  1,400  known  mutations  in  20  genes,  affecting  0.2%  of  the  population  [105].    Even  
though  many  afflicted  are  asymptomatic,  up  to  25%  will  develop  detrimental  symptoms  
or  sudden  death.    A  majority  of  the  mutations  are  in  sarcomeric  genes  including  β-­‐‑
myosin  heavy  chain  (MYH7),  myosin  binding  protein-­‐‑C  (MYBPC3),  cardiac  troponin  T  
(TNNT2),  myosin  light  chain  (MYL2),  cardiac  α-­‐‑actinin  (ACTC),  and  titin  (TTN)  [106,  
107].    Two  genes  account  for  the  majority  of  familial  hypertrophic  cardiomyopathy  
cases:  MYH7  mutations  account  for  35-­‐‑50%,  MYBPC3  mutations  account  for  20-­‐‑35%.    
The  mechanisms  behind  induction  of  hypertrophy  from  genetic  mutations  are  
controversial.    The  genetic  mutations  that  occur  correlate  to  calcium-­‐‑binding  domains,  
which  may  alter  the  ability  of  the  cardiac  muscle  to  contract,  increasing  stress  and  
downstream  signaling.    However,  this  has  not  been  empirically  demonstrated,  and  
studies  show  inconsistencies  as  to  whether  the  mutations  enhance  or  decrease  calcium  
sensitivity  [108,  109].    Mutations  in  calcineurin  have  not  been  implicated  in  familial  
hypertrophic  cardiomyopathy.    However,  it  is  conceivable  that  calcineurin  may  be  
activated  due  to  the  alterations  in  calcium  availability.    
In  addition  to  the  previously  mentioned  classification  of  cardiac  hypertrophy  
into  concentric  and  eccentric  types  according  to  dimensional  changes  in  the  cardiac  
chamber,  cardiac  hypertrophy  is  also  commonly  classified  into  pathological  or  
physiological  types  according  to  whether  the  observed  remodeling  is  maladaptive  in  
nature.    Physiological  cardiac  hypertrophy  occurs  during  growth  in  childhood,  exercise,  
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and  pregnancy  [110-­‐‑113].    Physiological  cardiac  hypertrophy  is  not  associated  with  
fibrosis,  arrhythmia,  or  heart  failure,  and  is  regulated  by  a  distinct  yet  overlapping  set  of  
signaling  factors  [91,  112].    IGF-­‐‑I  signaling  through  downstream  effectors  including  Ga/q  
PI3K,  AKT,  mTOR  and  GSK3β  regulates  physiological  cardiac  hypertrophy  [114].    In  
addition  to  having  distinct  signaling  pathways  and  phenotypes,  physiological  cardiac  
hypertrophy  does  not  appear  to  activate  the  fetal  gene  program  or  calcineurin-­‐‑NFAT  
signaling  [82,  115].    
Current  treatment  for  cardiac  hypertrophy  includes  an  array  of  pharmacological  
inhibitors  of  the  underlying  hypertension  which  also  show  efficacy  in  reducing  
hypertrophy,  including  angiotensin-­‐‑converting  enzyme  blockers,  angiotensin  receptor  
blockers,  β-­‐‑adrenergic  receptor  blockers,  and  calcium  channel  blockers  [88,  116,  117].    
However,  not  all  patients  are  responsive  to  current  treatment  and  the  disease  often  
progresses  even  in  the  responsive  patients  [118].    More  effective  treatment  is  needed  to  
target  multiple  aspects  of  this  complex  disease  involving  numerous  signaling  pathways,  
which  may  differ  from  patient  to  patient.    In  addition,  investigating  the  factors  involved  
in  pathological  versus  physiological  cardiac  hypertrophy,  such  as  calcineurin,  will  
provide  insight  into  combinations  of  molecules  within  the  pathway  that  should  be  either  
enhanced  or  suppressed  for  guiding  the  intricate  balance  between  overlapping  effects  of  
individual  signaling  pathways  towards  the  most  beneficial  phenotype.    Since  calcineurin  
is  strongly  associated  with  pathological  cardiac  hypertrophy,  discovering  novel  
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mechanisms  involved  in  calcineurin  downstream  function  has  high  potential  to  generate  
novel  therapeutic  targets.  
  
1.4 Animal models of cardiac hypertrophy 
Animal  models  have  the  advantage  of  the  ability  to  set  up  proper  control  
experiments,  to  have  enough  animals  in  each  experimental  group  to  perform  rigorous  
statistical  analysis,  and  to  genetically  or  pharmacologically  manipulate  to  rigorously  test  
specific  molecular  pathways.    Many  animal  models  have  been  used  to  facilitate  the  
study  of  cardiac  hypertrophy.    
  
1.4.1 Mouse (Mus musculus) 
The  mouse  model  has  been  extensively  used  to  study  cardiac  hypertrophy.    A  
large  community  of  researchers  and  tools  are  available,  including  transgenic  mice  with  
gene  knock-­‐‑out  or  overexpression  under  inducible  and  constitutive  promoters.    The  
generation  time  of  the  mouse  is  5-­‐‑8  weeks.    The  mouse  heart  is  similar  to  the  human  
heart  developmentally  and  structurally,  consisting  of  four  cardiac  chambers,  left  and  
right  atria  and  ventricles.    The  genes  expressed  controlling  cardiac  development  and  the  
components  of  the  sarcomeric  structure  are  highly  conserved  [119].    Of  note,  one  major  
discrepancy  between  the  mouse  and  human  hearts  is  the  neonatal  versus  adult  myosin  
heavy  chain  (MHC)  isoforms  expressed:  the  mouse  expresses  predominantly  β-­‐‑MHC  
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embryonically  with  a  complete  switch  to  α-­‐‑MHC  after  birth  [120]  while  humans  do  not  
undergo  this  switch  and  express  primarily  β-­‐‑MHC  in  the  adult  ventricles  [121,  122].    
Even  so,  both  mice  and  humans  display  an  increase  in  β-­‐‑MHC  percentage  with  
hypertrophy  (3%  to  25%  in  mice  and  75%  to  95%  in  humans)  [123,  124].  
The  most  commonly-­‐‑utilized  method  for  pressure-­‐‑overload  cardiac  hypertrophy  
is  by  using  transverse  aortic  constriction  (TAC),  mimicking  the  cardiac  hypertrophy  
response  of  human  patients  [125].    Many  studies  have  utilized  this  model  to  discover  
genes  that  are  necessary  for  cardiac  hypertrophy.    Inhibition  of  cyclic  GMP  
phosphodiesterase  5A  (PDE5A)  was  found  to  inhibit  TAC-­‐‑induced  cardiac  hypertrophy,  
including  heart  weight/tibia  length,  fractional  shortening,  and  fibrosis.    Other  genes  
found  to  mediate  TAC-­‐‑induced  cardiac  hypertrophy  include  calcium/calmodulin-­‐‑
dependent  protein  kinase  II  (CaMKII)  [126],  phosphoinositide  3-­‐‑kinase  (PI3K)  [127],  and  
growth  factor  receptor-­‐‑bound  protein  2  (Grb2)  [128].    Pharmacological  stimulation  
including  the  adrenergic  receptor  agonists  phenylephrine  (PE)  and  isoproterenol  [129],  
and  angiotensin  II  [130]  have  also  been  used  to  simulate  stress  conditions  and  cardiac  
hypertrophy.  
Cardiac  hypertrophy  in  mice  has  been  induced  genetically.    Genetic  models  have  
been  produced  to  express  molecules  in  the  multiple  signaling  pathways  inducing  
cardiac  hypertrophy.    One  of  these  molecules  is  Gαq.    Gαq  activates  signaling  
downstream  of  GPCRs  and  many  agonists  that  induce  cardiac  hypertrophy  such  as  ET-­‐‑1  
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and  AngII  described  in  the  previous  section  [91].    Mice  overexpressing  Gαq  in  the  heart  
display  significant  cardiac  hypertrophy,  reduced  fractional  shortening,  but  no  fibrosis  or  
myofibrillar  disarray  [131].    Another  molecule  is  the  calcium  storage  protein,  
calsequestrin.    Calcium  handling  is  significantly  altered  during  cardiac  hypertrophy  
[132].    Overexpression  of  calsequestrin  in  mice  results  in  cardiac  hypertrophy  and  fetal  
gene  expression  [133].    Protein  kinase  C  (PKC)  regulates  angiotensin-­‐‑induced  gene  
activation  [134],  and  overexpression  of  the  PKCβ2  and  ε  isoforms  induce  cardiac  
hypertrophy  while  only  the  PKC  isoform  mediates  contractile  dysfunction  [135,  136].    In  
this  respect,  expression  of  a  small  8  a.a.  peptide  encoding  the  region  on  the  receptor  of  
activated  PKC  (ΨεRACK),  which  acts  as  a  PKCε  agonist,  induced  a  minor  hypertrophy  
with  decreased  fractional  shortening  [137].    Genetic  manipulations,  though  not  able  to  
represent  the  full  scale  of  alterations  in  a  clinical  setting,  are  useful  in  delineating  the  
regulation  of  individual  pathways.  
  
1.4.2 Rat (Rattus norvegicus) 
The  rat  model  has  been  extensively  used  to  study  cardiac  hypertrophy,  taking  
advantage  of  the  larger  size  for  making  hemodynamic  measurements.    Like  the  mouse  
heart,  the  rat  heart  is  also  similar  to  the  human  heart  in  structure.    The  rat  generation  
time  is  longer  than  that  of  the  mouse  (8-­‐‑12  weeks).    Hypertrophy  models  for  rats  include  
aortic  banding  [138,  139]  and  norepinephrine  stimulation  [140],  and  have  been  useful  in  
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determining  molecular  and  cellular  aspects  of  cardiac  hypertrophy  [141-­‐‑143].    Due  to  
their  larger  size  and  longer  generation  time  compared  to  mice,  transgenic  rats  are  more  
difficult  to  generate  though  tools  are  available  [144].    Transgenic  rats  expressing  renin,  
upstream  to  the  generation  of  angiotenisin  II,  develop  cardiac  hypertrophy  without  
signs  of  heart  failure  [145].  
  
1.4.3 Other animal models 
Many  other  larger  mammalian  models  have  been  used  to  study  cardiac  
hypertrophy.    These  include  aortic  constriction  or  pulmonary  artery  constriction  in  
rabbits,  hamsters,  dogs,  cats,  pigs,  ferrets,  and  sheep.    These  models  have  the  advantage  
of  being  closer  in  size  and  electrophysiology  to  humans,  with  disadvantages  of  longer  
generation  times  and  less  widespread  genetic  tools  [146].  
The  zebrafish  heart  also  possesses  high  conservation  in  developmental  and  
structural  genes  compared  to  humans  [147].    The  zebrafish  heart  undergoes  similar  early  
morphologic  changes  during  development  without  septation,  resulting  in  a  2  chamber  
heart  with  one  atrium  and  one  ventricle.    Zebrafish  have  the  advantages  of  ease  of  care,  
low  generation  time,  high  yield,  and  well-­‐‑developed  genetic  manipulation  tools  [148].    
Although  extensive  research  has  investigated  cardiac  development  and  regeneration  in  
zebrafish  [148-­‐‑150],  fewer  studies  have  been  performed  regarding  cardiac  hypertrophy.    
Knocking  down  the  MYBPC  homologue,  which  causes  familial  hypertrophic  
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cardiomyopathy  in  humans,  results  in  significant  cardiac  hypertrophy  with  increased  
wall  thickness,  decreased  diastolic  relaxation  rate,  and  impaired  calcium  reuptake  [151].    
Anemic  fish  with  a  mutation  in  erythrocyte-­‐‑specific  transmembrane  protein  band  3  
(tr265)  resulted  in  significant  cardiac  hypertrophy  with  increased  heart  size,  
proliferation,  myofibrillar  disarray,  and  fetal  gene  activation  [152].  
The  model  used  for  my  study,  the  fruitfly  (Drosophila  melanogaster),  is  the  
smallest  and  most  efficient  system  for  performing  genetic  studies  with  a  visible  heart,  
and  will  be  discussed  in  detail  in  the  following  chapters.  
  
1.5 Drosophila as a model system 
Drosophila  is  well  adapted  for  genetic  studies:  it  has  a  relatively  short  generation  
time  (2  weeks),  well  developed  genetic  manipulation  methods,  and  well  developed  
genetic  resources,  including  mutation  stocks  and  vectors  for  making  transgenics  [153-­‐‑
155].      
The  Gene  Disruption  Project  (GDP)  and  Exelixis  collections  have  focused  efforts  
on  generating  at  least  one  gene  disruption  for  every  gene  [156]  and  maximal  coverage  of  
the  entire  Drosophila  genome  with  deficiency  lines  [157,  158].    Genetic  disruptions  
include  many  different  transposable  element  insertion  lines,  large  stretches  of  DNA  with  
inverted  repeats  on  either  end  that  are  recognized  by  specific  transposase,  allowing  
integration  into  the  genome.    The  first  transposable  element  discovered  and  utilized  in  
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the  fruitfly  was  the  P-­‐‑element,  recognized  by  the  P  protein  transposase  [159,  160].    The  
piggyBac  element,  discovered  in  the  cabbage  looper  moth  Trichoplusia  ni  [161],  and  the  
Minos  element,  discovered  in  Drosophila  hydei  [162],  have  also  subsequently  been  
utilized  for  gene  disruption.    Each  of  these  transposable  elements  have  insertion  site  
preferences,  making  it  necessary  to  utilize  different  elements  for  maximal  coverage  of  
the  genome.    Deficiency  stocks  are  generated  by  introducing  Flp-­‐‑FRT  sites  and  Flp  
recombinase  to  induce  recombination  between  two  inserted  elements,  deleting  the  
portion  of  the  chromosome  between  the  two  elements  in  progeny  [157].      
Many  systems  are  also  available  to  generate  knock-­‐‑down  or  knock-­‐‑out  of  gene  
expression  including  RNAi,  CRISPR,  and  TALEN  systems.    The  emerging  CRISPR  
system  allows  for  specific  gene  targeting  with  a  short  guide  RNA  and  has  been  utilized  
in  several  studies  and  reported  to  have  less  off-­‐‑target  effects  than  RNAi  [163-­‐‑165].    The  
TALEN  system  is  more  specific  but  requires  more  specialized  techniques  [166-­‐‑168].    
CRISPR  and  TALEN  systems  can  also  be  utilized  for  site-­‐‑specific  mutagenesis  and  
genetic  knock-­‐‑in  [166,  169,  170].  
In  addition  to  gene  disruption,  transposable  element  constructs  are  also  widely  
utilized  for  making  transgenic  flies  expressing  a  gene  of  interest  and  for  enhancer  or  
protein  trapping.    A  transposable  element  insertion  carrying  a  promoter  sequence  
driving  a  specific  gene  of  interest  generates  an  overexpression  transgenic  fly.    The  
Gal4/UAS  system  greatly  enhanced  the  efficiency  and  versatility  of  gene  expression.    
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Gal4  is  a  transcription  factor  that  specifically  recognizes  the  UAS  (Upstream  Activation  
Sequence)  promoter,  driving  expression.    By  using  a  bipartite  system,  a  gene  of  interest  
downstream  to  a  UAS  promoter  can  be  crossed  to  different  driver-­‐‑Gal4  lines  to  
efficiently  express  a  gene  of  interest  in  different  tissues  or  express  different  genes  with  
the  same  driver  without  going  through  the  lengthy  process  of  embryo  injection,  
propagation,  and  mapping  [171].    Enhancer  trapping  involves  transposable  elements  
carrying  a  reporter  gene,  often  lacZ  or  GFP  fused  to  a  minimal  promoter,  which  can  
utilize  enhancer  elements  [172].    Protein  trapping  involves  an  insertion  without  a  
minimal  promoter  in  an  artificial  exon  to  examine  the  expression  of  GFP  fusion  proteins  
[173,  174].    The  above  applications  are  only  part  of  the  many  strategies  and  techniques  
that  have  been  developed  and  utilized  in  Drosophila  research.  
  
1.6 The Drosophila heart 
The  Drosophila  melanogaster  heart  consists  of  a  tube-­‐‑like  structure  running  along  
the  center  of  the  abdominal  dorsal  cuticle  (Figure  2).    This  structure  is  formed  by  a  single  
layer  of  52  pairs  of  tin-­‐‑expressing  (104  total)  cells,  one  on  each  side  of  the  cardiac  tube  
[175].    At  the  intersection  of  each  abdominal  segment,  a  pair  of  valve-­‐‑like  cells,  ostia,  
allow  hemolymph  to  enter  the  cardiac  tube  from  the  abdomen  with  contraction  of  the  
cardiac  tube.    The  beating  heart  plays  multiple  important  roles  in  maintaining  vitality  of  
the  fly:  hemolymph  carries  nutrients  [176,  177],  and  immune  cells  (hemocytes)  [178];  
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hemoglobins  carry  oxygen  (intracellular  to  tracheal  and  fat  body  cells)  [179],  and  
displacement  of  hemolymph  in  the  abdominal  cavity  assists  with  airflow  in  the  tracheal  
system  for  ventilation  [180,  181].    In  a  Drosophila  RNAi  screen,  cardiac-­‐‑specific  knock-­‐‑
down  of  regulators  of  heart  function  have  been  shown  to  induce  early  death  [182],  




Figure  2:  The  Drosophila  melanogaster  circulatory  system.  
A  longitudinal  view  of  the  Drosophila  melanogaster  circulatory  system  is  shown.    
The  heart  (dorsal  vessel)  is  a  tube,  shown  in  red,  lying  underneath  the  cuticle,  adjacent  
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according  to  the  cuticle  pattern.    Corresponding  ostia  (valve-­‐‑like  structures  that  allow  
hemolymph  to  come  through)  are  also  labeled.  [154]  
  
  
Several  methods  have  been  employed  by  different  groups  to  study  cardiac  
morphology  and  function.    The  fine  structure  of  the  Drosophila  heart  can  be  visualized  by  
a  number  of  approaches:  paraffin  sectioning  with  H&E  stain,  transmission  electron  
microscopy,  and  visualization  under  a  fluorescence  microscope  after  dissection  by  
exposing  the  heart  from  the  abdominal  side  with  immunostaining  [183,  184].    These  
methods  can  visualize  the  structure  and  morphology  of  the  heart  in  detail,  but  can  not  
provide  functional  data.    The  beating  heart  can  be  monitored  by  dissecting  the  heart  of  
the  adult  fly  or  by  immobilizing  the  larva  (the  beating  heart  is  visible  under  the  
transparent  cuticle)  and  recording  of  transmitted  light  under  a  dissection  microscope  
[185].    Software  programs  record  the  beating  heart  through  time,  producing  an  efficient  
way  to  visualize  and  monitor  heart  rate  [186].    However,  this  method  only  detects  heart  
rate  and  does  not  allow  for  analysis  of  function.    The  semi-­‐‑automated  optical  heartbeat  
analysis  (SOHA)  method  involves  two  software  programs  and  allows  for  monitoring  of  
heart  rate  and  cardiac  dimensions  and  contractile  function  on  the  left-­‐‑right  axis  over  
time  [187].    However,  this  method  involves  careful  dissection  of  the  heart  to  avoid  
damage  and  the  heart  rate  is  significantly  altered  from  loss  of  neuronal  input  [188].    
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Optical  coherence  tomography  (OCT)  is  used  to  efficiently  monitor  intact  awake  
Drosophila  heart  [189].    Real-­‐‑time  monitoring  allows  for  detection  of  the  size  of  the  
cardiac  lumen  through  the  cardiac  cycle,  from  end-­‐‑diastole  (the  heart  at  its  most  relaxed  
state)  to  end-­‐‑systole  (the  heart  at  its  most  constricted  state)  (Figure  3).    Therefore,  OCT  
has  been  utilized  in  my  study  for  making  cardiac  measurements.  
  
  
Figure  3:  Visualizing  the  beating  Drosophila  heart  with  OCT  in  intact,  awake  
flies.  
The  adult  Drosophila  heart  can  be  monitored  in  real  time  using  OCT.    M-­‐‑mode  
images  are  captured  by  collecting  data  from  one  straight  line  through  the  transverse  
section  of  the  heart  through  time.    End  diastolic  dimensions  (the  heart  at  its  most  relaxed  
state)  and  end  systolic  dimensions  (the  heart  at  its  most  constricted  state)  are  easily  
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Drosophila  is  a  good  model  for  investigating  the  heart.    Many  pathways  are  
conserved  among  mammalian  and  Drosophila  cardiac  development  [153,  190-­‐‑193].    These  
include  cardioblast  specification  genes  like  Drosophila  tinman  (tin)  (homologous  to  
mouse  Nkx2.5),  Drosophila  decapentaplegic  (dpp)  (homologous  to  mouse  BMP),  and  
cardiomyocyte  differentiation  genes  like  Mef2,  which  are  conserved  in  Drosophila  and  
mammals.    In  addition,  the  main  machinery  for  muscle  contraction  including  actin,  
myosin  heavy  chain,  myosin  light  chain,  and  tropomyosin,  are  also  conserved  between  
Drosophila  and  mammals.    In  fact,  strategies  based  on  fly  genetics  have  been  used  to  
identify  genes  that  cause  or  modify  cardiomyopathies  [182,  189,  194].    Many  studies  
have  analyzed  genes  causing  cardiac  dilation  [184,  189,  195-­‐‑197]  or  arrhythmia  [188,  198-­‐‑
200],  while  cardiac  hypertrophy  has  been  less  investigated.    One  study  found  that  
expressing  constitutively  active  EGFR  or  Ras  in  the  heart  induces  cardiac  wall  thickness  
in  the  fly  [194].  
In  addition  to  the  above  advantages,  since  Drosophila  do  not  express  calcineurin-­‐‑
regulated  NFAT  [80],  this  increases  the  possibility  of  discovering  novel  genes  
downstream  of  calcineurin  activation.    Therefore,  we  conducted  studies  using  fly  
genetics  to  identify  novel  modifiers  of  cardiac  calcineurin-­‐‑induced  cardiomyopathy.  
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1.7 Calcineurin screens in the fly  
Previously,  two  independent  screens  have  been  conducted  to  identify  modifiers  
of  calcineurin  phenotypes  in  tissues  other  than  the  heart  [10,  11].    The  deficiency  regions  
identified  are  summarized  in  Table  1.    Sullivan  and  Rubin  performed  a  dominant  
modifier  screen  in  the  Drosophila  eye  and  found  five  suppressor  and  four  enhancer  loci  
[10].    Two  modifier  genes,  CanB2  and  sprouty  were  identified.    However,  modifier  genes  
within  the  seven  other  broadly  mapped  loci  remained  uncharacterized.    Gajewski  et  al  
found  seven  different  deletion  intervals  that  suppressed  the  lethal  phenotype  of  
constitutively  active  calcineurin  driven  by  the  general  mesodermal  driver  24B  [11].    
Interestingly,  only  one  interval  overlapped  between  these  two  studies  on  chromosome  
3L,  cytolocation  66F5  (gray,  Table  1).    This  is  the  region  where  I  initiated  my  study.  
  
Table  1:  Suppressor  regions  in  previous  calcineurin  screens.  
Chr   Cytolocation   Region   Driver   Overlapping  
2L   21A1-­‐‑21B8   326.5  kbp,  56  genes   Mesoderm   No  
2R   43E16,  CanB2   Modifier  gene  found,  CanB2   Eye  
Mesoderm  
Yes  
2R   46A-­‐‑46C   351  kbp,  51  genes  
Modifier  gene  found,    
Mef2  (preliminary)  
Mesoderm   No  
2R   59A1-­‐‑59D4   609  kbp,  109  genes   Mesoderm   No  
3L   60E2-­‐‑60E12   221  kbp,  40  genes   Mesoderm   No  
3L   63D2,  Sty   Modifier  gene  found,  sty   Eye   No  
3L   65E-­‐‑68C   4,621  kbp,  >500  genes   Eye   Yes  
3L   66F5   28.43  kbp,  4  genes   Mesoderm   Yes  
3L   76B1-­‐‑76B5   158  kbp,  23  genes   Mesoderm   No  
3R   86A-­‐‑89B   6,374  kbp,  >500  genes   Eye   No  
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1.8 Specific aims 
Calcineurin  plays  an  important  regulatory  role  in  cardiac  hypertrophy.    Cardiac  
hypertrophy  is  a  deleterious  condition  which  pends  novel  targets  for  therapy.    The  
Drosophila  melanogaster  is  an  efficient  model  for  performing  screens  to  discover  novel  
modifier  genes.  
Accordingly,  the  specific  aims  I  have  accomplished  in  this  study  are  as  follows:  
1) Establish  a  reliable  model  for  discovering  novel  modifiers  of  
calcineurin-­‐‑induced  cardiomyopathy  in  the  Drosophila  melanogaster  
heart.  
2) Discover  and  characterize  novel  modifiers  of  calcineurin-­‐‑induced  
cardiomyopathy  in  the  Drosophila  melanogaster  heart.  
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2.1 Drosophila stocks 
The  following  Drosophila  stocks  were  obtained  from  the  Bloomington  Drosophila  
Stock  Center:  w1118,  Df(3L)ED4416,  Df(3L)ED4421,  Df(3L)ED4414,  Df(3L)ED4415,  
Df(3L)ED4413,  Df(3L)BSC130,  Df(3L)BSC170,  Df(3L)BSC390,  Df(2R)X1,Mef2X1/CyOAdhnB,  
sty∆5/TM3,P{35UZ}2,  P{EP}CanB2EP774,  PBac{PB}Galkc03848,  Mi{ET1}GalkMB10638,  
P{wHy}galectinDG25505,  P{GD4334}v16746(Doc1  RNAi),  P{TRiP.JF02222}attP2  (Doc1  RNAi),  
P{GD4335}v37634  (Doc2  RNAi),  P{TRiP.JF02223}attP2  (Doc3  RNAi),  snaSco/SM6a,  
P{hsILMiT}2.4,  P{en2.4-­‐‑Gal4}e16E  (e16E-­‐‑Gal4),  P{GAL4-­‐‑dpp.blk1}40C.6  (dpp-­‐‑Gal4),  P{Act5C-­‐‑
GAL4}25FO1  (Act5C-­‐‑Gal4),  P{GAL4-­‐‑Mef2.R}3  (mef2-­‐‑Gal4).    The  Drosophila  stock  
PBac{PB}Argkf05255  was  obtained  from  the  Exelixis  Collection  at  Harvard  Medical  School.    
The  following  Drosophila  stocks  were  obtained  from  the  Vienna  Drosophila  RNAi  Center:  
P{KK107841}VIE-­‐‑260B  (Galk  RNAi),  P{GD4334}v16747  (Doc1  RNAi),  P{GD4335}v37634  
(Doc2  RNAi).    The  double  balancer  line  WR135  was  kindly  provided  by  Dr.  Robin  
Wharton.    The  P{tinC-­‐‑Gal4}  line  was  kindly  provided  by  Dr.  Manfred  Frasch  [201].    The  
UAS-­‐‑Mef2  line  was  kindly  provided  by  Dr.  Michael  Taylor  [64,  202].    The  TnI  mutant  
hdp2  was  a  kind  gift  from  Dr.  Jim  Vigoreaux  and  had  previously  been  shown  to  induce  
flight  muscle  [203]  and  cardiac  enlargement  [189]  phenotypes.    The  P{tinC-­‐‑GFP}  (tinC-­‐‑
GFP)  line  was  generated  as  previously  described  by  inserting  the  304  bp  tinC  genetic  
sequence  into  the  pGreen-­‐‑H-­‐‑Pelican  vector  [184,  201,  204]  and  the  construct  injected  at  
the  Duke  University  Model  Systems  Genomics  Facility.    The  tinC-­‐‑YCanAact,  tinC-­‐‑
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FCanAact,  and  UAS-­‐‑YCanAact  Drosophila  lines  were  generated  at  the  Duke  University  
Model  Systems  Genomics  Facility  by  injecting  the  corresponding  constructs  into  
Drosophila  embryos.  
  
2.2 Cloning  
The  tinC-­‐‑YCanAact,  tinC-­‐‑FCanAact,  UAS-­‐‑YCanAact,  and  UAS-­‐‑Galk  constructs  for  
transgenic  expression  were  generated  using  standard  procedures.    Constitutively  active  
calcineurin  (CanAact)  was  generated  from  Drosophila  cDNA  as  previously  described  by  
amplifying  Pp2B-­‐‑14D  with  corresponding  primers,  excluding  the  c-­‐‑terminus  auto-­‐‑
inhibitory  domain  [10].    The  following  primers  were  used:  ATG  TCT  TCG  AAT  AAC  
CAG  AGC  AGC  AG  (forward)  and  TCA  GTT  GCG  TAT  CAC  CTC  CTT  GCG  CA  
(reverse).    The  amplified  product  was  blunt-­‐‑end  ligated  into  TOPO  vector  (Invitrogen,  
Inc.)  and  subsequently  amplified  with  corresponding  restriction  enzyme  sites.    The  YFP  
tag  was  added  to  the  N-­‐‑terminus  of  CanAact  by  cutting  with  the  corresponding  
restriction  enzyme  sites  and  ligating  into  the  pEYFP-­‐‑C1  vector.    For  the  Flag  tag,  the  full-­‐‑
length  sequence  of  the  tag  was  added  on  the  amplification  primer  to  directly  generate  a  
tagged  sequence.    For  the  tinC-­‐‑CanAact  constructs,  the  tagged  sequence  of  either  YFP-­‐‑
tagged  CanAact  (YCanAact)  or  Flag-­‐‑tagged  CanAact  (FCanAact)  were  then  cut  and  ligated  
into  the  pCaSpeR5  Drosophila  expression  vector.    This  vector  contained  the  tinC-­‐‑hsp70  
promoter  to  the  N-­‐‑terminus  as  previously  described  [184].    The  UAS-­‐‑YCanAact  construct  
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was  generated  by  cutting  and  ligating  the  tagged  YCanAact  sequence  with  restriction  
enzyme  sites  into  a  pUAST  Drosophila  vector.    This  vector  consists  of  the  UAS-­‐‑promoter,  
which  drives  expression  of  the  transgene  upon  binding  of  the  Gal4  transcription  factor.    
The  catalytic  activity  of  N-­‐‑terminal  YFP-­‐‑tagged  CanAact  has  been  confirmed  in  studies  by  
a  number  of  investigators,  using  well  characterized  NFAT  reporter  assays  [205,  206],  
NFAT  phosphorylation  assays  [205],  and  NF-­‐‑κB  reporter  assays  [207].  
  
2.3 Histology  
Histology  was  performed  according  to  standard  procedures  [208].    3  -­‐‑  5  day  old  
flies  of  the  corresponding  genotypes  were  collected  and  washed  briefly  with  70%  
ethanol  to  clean  the  surface  and  facilitate  infiltration  of  the  fixative  and  fixes  the  fly  
hearts  at  the  most  relaxed  state,  end-­‐‑diastole.    To  assess  this,  OCT  images  were  
measured  and  compared  between  alive  w1118  end-­‐‑diastolic  dimension  (46.37  ±  4.91  
microns,  N=9)  and  the  size  of  the  heart  after  EtOH  fixation  (50.19  ±  6.09  microns,  N=9),  
P=N.S.,  student’s  t  test.    Flies  were  then  fixed  in  formalin  at  4°C  overnight.    The  next  day,  
flies  were  washed  in  PBS  and  subsequently  through  an  ethanol  gradient  up  to  a  solution  
consisting  of  95%  ethanol  with  5%  glycerol  to  soften  the  cuticle  and  facilitate  the  
sectioning  process.    The  flies  were  then  submerged  in  xylene,  and  then  incubated  at  60°C  
with  one  40  minute  paraffin  wax  wash  followed  by  incubation  overnight  under  vacuum  
in  liquid  wax.    Samples  were  then  positioned  in  molds  and  the  wax  allowed  to  harden.    
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8  µμm  sections  were  cut  using  a  standard  microtome  and  adhered  to  poly-­‐‑L-­‐‑lysine-­‐‑coated  
glass  slides.    After  drying  overnight  on  a  37°C  slide  warmer,  slides  were  collected  for  
staining.    Standard  hematoxylin  and  eosin  (H&E)  staining  procedures  were  performed.    
Slides  were  warmed  vertically  at  50°C  for  30  minutes  and  subsequently  submerged  in  
xylene  before  going  into  an  ethanol  gradient  to  rehydrate  into  water  before  performing  
hematoxylin  &  eosin  staining  according  to  standard  procedures.    The  slides  were  then  
dehydrated  through  an  ethanol  gradient  into  xylene  and  mounted  in  Cytoseal  XYL  
mounting  medium  (Thermo  Fisher  Scientific  Inc.).    Slides  were  then  allowed  to  harden  
overnight  at  37°C.    Images  were  captured  using  the  PAXcam  ARC  camera  connected  to  
the  Olympus  IX70  inverted  microscope  and  quantified  for  lumen  area  and  perimeter  in  
imageJ,  calibrated  with  a  hemocytometer  measuring  50  µμm.    Locating  the  position  along  
the  cardiac  tube  for  measurement  was  determined  as  previously  described  by  examining  
the  portion  of  the  sections  where  an  en  face  section  of  the  cardiac  tube  was  visible  and  
measuring  three  consecutive  sections  three  sections  (24µμm)  posterior  to  this  section  
[184].  
  
2.4 Optical coherence tomography (OCT)  
End-­‐‑diastolic  dimension  and  end-­‐‑systolic  dimension  were  measured  using  
optical  coherence  tomography  (OCT)  (Bioptigen,  Inc.  Durham,  NC)  as  previously  
described  [189].    Briefly,  7-­‐‑10  days  post-­‐‑eclosion,  female  Drosophila  were  placed  in  
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GelWax  medium  and  allowed  to  awaken.    M-­‐‑mode  images  through  the  conical  chamber  
were  collected  for  immobilized  awake  Drosophila.    End-­‐‑diastolic  and  end-­‐‑systolic  
dimensions  were  measured  in  ImageJ,  calibrated  to  a  125µμm  thick  glass  slide.    Fractional  
shortening  was  calculated  as  (End-­‐‑diastolic  dimension  minus  end-­‐‑systolic  
dimension/End-­‐‑diastolic  dimension)  x  100%  and  used  as  a  measure  of  cardiac  
contractility.  
Several  types  of  controls  were  used  and  compared  for  our  study:  w1118  used  
routinely  in  our  lab  as  a  control  (Flybase  ID:  FBst0003605),  w1118  used  to  create  
transgenics  from  the  Duke  University  Model  Systems  Genetics  Facility  (Flybase  ID:  
FBst0006326),  tinC-­‐‑Gal4,  tinC-­‐‑Gal4  heterozygous  with  w1118,  tinC-­‐‑GFP  and  tinC-­‐‑GFP  
heterozygous  with  w1118.    We  performed  a  one-­‐‑way  ANOVA  comparing  OCT  
measurements  between  all  control  groups  and  showed  that  none  were  significantly  
different  from  each  other  (Figure  4).  
  
  
     36  
  
Figure  4:  End-­‐‑diastolic  dimensions  and  fractional  shortenings  are  not  different  
among  control  flies  used  in  this  study  
Quantitative  results  from  OCT  images  for  several  control  lines  used  in  this  study:  
w1118  (FBst0003605)  control,  w1118  (FBst0006326)  from  the  Duke  University  Model  System  
Genomics  Facility  for  generation  of  transgenic  flies,  tinC-­‐‑Gal4  heterozygous  from  cross  
with  w1118  (FBst0003605),  homozygous  tinC-­‐‑Gal4,  tinC-­‐‑GFP  heterozygous  from  cross  with  
w1118  (FBst0003605),  and  homozygous  tinC-­‐‑GFP.    End-­‐‑diastolic  dimensions  and  fractional  
shortenings  were  not  significantly  different  among  the  control  lines  used  in  this  study.    
One-­‐‑way  ANOVA  with  Bonferroni  correction.    Numbers  on  each  bar  represent  number  
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2.5 Confocal microscopy  
Flies  that  harbored  tinC-­‐‑GFP  or  tinC-­‐‑YCanAact  were  collected  1-­‐‑2  days  after  
eclosion,  and  dissected  as  previously  described  [184]  by  removing  the  ventral  side  of  the  
abdomen  and  exposing  the  heart  tube.    Immunohistochemistry  was  performed  
according  to  standard  procedures  as  previously  described  [184]  using  5%  BSA  in  TBS  as  
the  blocking  reagent  with  a  rabbit  anti-­‐‑GFP  antibody  (Invitrogen,  Inc.),  and  Alexa  
Fluor488  goat  anti-­‐‑rabbit  secondary  antibody  (Invitrogen,  Inc.).    After  immuno-­‐‑staining,  
the  Drosophila  heart  was  visualized  under  a  Zeiss  LSM510  confocal  microscope.    
Consecutive  Z-­‐‑stacks  were  taken  at  1µμm  intervals,  and  projected  to  form  a  3D  image  in  
the  LSM  image  browser  software.  
For  capturing  images  of  stage  16  embryos,  tinC-­‐‑GFP  or  tinC-­‐‑YCanAact  flies  were  
collected  and  allowed  to  lay  eggs  on  apple  juice  agar  plates  for  2  hours.    14-­‐‑16  hours  
after  egg  laying,  embryos  were  collected  in  an  embryo  collection  apparatus  by  first  
dechorionating  embryos  in  50%  bleach  and  washing  with  distilled  water.    Embryos  were  
then  imaged  in  VECTASHIELD®  (Vector  Laboratories,  Inc.)  under  the  Zeiss  LSM510  
confocal  microscope.  
  
2.6 Fluorescence microscopy for determining nuclei number in 
Drosophila hearts 
tinC-­‐‑GFP  or  tinC-­‐‑YCanAact  flies  were  crossed  with  tinC-­‐‑Gal4,  UAS-­‐‑nuclear  RFP  
flies  and  the  offspring  were  collected  1-­‐‑2  days  after  eclosion.    Hearts  were  exposed  by  
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dissection  as  previously  described  for  confocal  microscopy  and  imaged  without  staining  
under  the  confocal  microscope  [184].    Nuclei  from  visualization  of  RFP  were  counted  
visually  to  determine  the  number  of  cardiomyocytes  present  in  each  heart.    Ostia  cells  
and  cuticle  patterning  were  used  to  determine  the  abdominal  segment  boundaries  and  
nuclei  number  was  counted  for  abdominal  segments  2  and  3  because  the  first  and  last  
couple  abdominal  segments  were  often  damaged  in  the  dissection  process.  
  
2.7 Precise excision of the Minos insertion in galactokinase 
The  Minos  insertion  in  Galk,  Mi{ET1}GalkMB10638,  was  excised  precisely  according  
to  standard  transposable  element  excision  procedures  [162,  209].    Briefly,  the  
Mi{ET1}GalkMB10638  males  were  crossed  to  virgin  females  containing  the  Minos  
transposase  snaSco/SM6a,  P{w+mC=hsILMiT}2.4.    After  three  days,  adult  flies  were  removed,  
and  the  embryos  were  heat  shocked  for  1  hour  in  a  37˚C  water  bath  for  4  consecutive  
days.    Male  progeny  were  selected  for  the  presence  of  the  Minos  insertion  and  the  Minos  
transposase  according  to  eye  color  (the  Minos  element  expresses  GFP,  and  Minos  
transposase  expresses  a  red  eye  color  from  mini-­‐‑white  in  the  insertion)  and  crossed  to  the  
double  balancer  fly  stock  WR135.    Male  progeny  were  selected  for  the  absence  of  GFP  
and  mini-­‐‑white,  indicating  a  successful  excision,  and  crossed  again  to  WR135  virgin  
females.    Progeny  harboring  excisions  were  crossed  to  each  other  to  make  a  homozygous  
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stock.    These  stocks  were  assayed  for  the  presence  of  a  precise  excision  using  primers  
sequencing  through  the  affected  genomic  region.  
  
2.8 Real-time RT-PCR 
Real-­‐‑time  RT-­‐‑PCR  was  performed  to  determine  the  expression  level  of  genes.    
Drosophila  were  collected  3-­‐‑5  days  after  eclosion  and  5  whole  flies  were  collected  or  10-­‐‑15  
fly  hearts  were  dissected  for  each  group.    RNA  was  extracted  using  RNA-­‐‑Bee  RNA  
isolation  reagent  (Amsbio)  according  to  the  manufacturer’s  protocol.    SuperScript  II  
(Invitrogen)  reverse  transcription  according  to  the  manufacturer’s  protocol  was  followed  
by  real-­‐‑time  PCR  analysis  using  taqman  probes  (probe:  Dm01801608_g1,  Applied  
Biosystems,  Inc.).  
  
2.9 Life span 
Drosophila  were  collected  1-­‐‑2  days  after  eclosion.    10  males  and  10  females  were  
kept  in  the  same  vial  and  food  changed  every  2-­‐‑3  days.    A  total  of  6  vials  were  
monitored  for  each  group.    The  number  of  remaining  flies  was  monitored  daily.    Data  
was  analyzed  using  GraphPad  Prism  software  and  statistical  analysis  was  performed  
with  a  Mantel-­‐‑Cox  test  for  significance.  
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2.10 Wing vein phenotype 
Drosophila  from  the  respective  crosses  were  collected  at  3-­‐‑5  days  after  eclosion.    
The  wings  were  detached  using  forceps  and  the  ventral  surface  was  placed  face  down  
on  GelWax  plates.    The  wings  were  examined  for  abnormalities  under  a  dissection  
microscope  at  40x  or  imaged  under  a  Leica  M165FC  Fluorescence  stereo  microscope  
equipped  with  a  Leica  DFC310FX  camera  at  50x.    A  range  of  wing  vein  abnormalities  
were  observed,  which  were  divided  into  normal,  abnormalities  of  the  posterior  
crossvein  (PCV),  or  abnormalities  of  both  the  PCV  and  the  longitudinal  vein  5  (L5).    The  
number  of  wings  under  each  category  of  wing  vein  phenotype  were  counted  for  each  
group  and  the  percentage  of  total  wings  counted  was  calculated.    Statistical  significance  
to  detect  for  a  rescue  of  the  abnormal  wing  vein  phenotype  (pooling  the  two  different  
types  of  wing  vein  abnormalities)  with  the  Df(3L)ED4416  deficiency  was  determined  
using  Fisher’s  exact  test.    Tissue-­‐‑specific  expression  of  CanAact  with  dpp-­‐‑Gal4,  Act5C-­‐‑
Gal4,  and  mef2-­‐‑Gal4  was  analyzed  similarly  by  counting  the  number  of  progeny  with  the  
respective  phenotypes  according  to  the  crosses  and  genotypes  described  in  the  figure  
legend.  
  
2.11 Cell Culture 
H9c2  rat  embryonic  cardiomyoblasts  and  NIH-­‐‑3T3  mouse  fibroblasts  were  
obtained  from  ATCC  and  maintained  according  to  standard  procedures.    H9c2  cells  
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were  maintained  in  DMEM  medium  while  NIH-­‐‑3T3  mouse  fibroblasts  were  maintained  
in  RPMI  medium.    Cells  were  passaged  regularly  by  detaching  with  0.25%  trypsin-­‐‑
EDTA  solution.    Transfection  with  NFAT-­‐‑GFP  was  performed  with  lipofectamin®  2000  
(Life  Technologies,  Inc.)  according  to  manufacturer’s  protocols.    After  24  hours  of  
lipofectamine®  transfection,  cells  were  detached  from  the  plate  and  replated  onto  poly-­‐‑L-­‐‑
lysine  coated,  collagen  pretreated  glass  bottom  confocal  dishes,  allowed  to  attach,  and  
transfected  with  predesigned  siRNA  to  Galk1  (Life  Technologies,  Inc.)  with  
GeneSilencer®  (Genlantis)  according  to  manufacturer’s  protocol.    Cells  were  serum  
starved  for  24  hours,  treated  with  or  without  0.1  µμM  ionomycin  for  1  hour.    After  
washing  with  PBS,  fixation  with  4%  paraformaldehyde  followed  by  another  PBS  wash  (3  
times,  10  minutes  each),  cells  were  kept  in  VECTASHIELD®  (Vector  Laboratories,  Inc.)  
before  imaging  under  the  Zeiss  LSM510  confocal  microscope.  
  
2.12 Statistical analysis 
All  statistical  analysis  was  performed  using  GraphPad  Prism  software.    One-­‐‑way  
ANOVA  with  Bonferroni  correction  was  used  to  determine  significance  for  multiple  
comparisons  and  student’s  t  test  was  used  for  single  comparisons.    Mantel-­‐‑Cox  rank  test  
was  used  to  compare  survival  curves,  two-­‐‑way  ANOVA  was  used  to  compare  the  
progression  of  Drosophila  heart  function  with  age,  and  Fisher’s  exact  test  was  used  to  
determine  rescue  for  wing  and  lethality  phenotypes.






Chapter 3. Generating and characterizing the calcineurin 
fly 
  
In  order  to  use  deficiency  screening  to  discover  novel  calcineurin  modifiers,  I  
generated  sensitized  Drosophila  lines  expressing  constitutively  active  calcineurin  
(CanAact)  by  expressing  CanAact  directly  under  control  of  the  cardiac-­‐‑specific  driver  tinC-­‐‑  
(tinC-­‐‑CanAact)  or  under  control  of  the  UAS  driver  (UAS-­‐‑CanAact).    Driving  CanAact  in  the  
heart  induces  a  significant  cardiac  enlargement  phenotype.  
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3.1 Making the sensitized CanAact Drosophila line 
  
3.1.1 The cardiac-specific constitutively active calcineurin (CanAact) 
construct 
Several  components  were  utilized  in  the  vector  to  make  the  transgenic  fly:  1)  
constitutively  active  calcineurin  (CanAact);  2)  a  tag  for  detecting  transgene  expression;  
and  3)  a  cardiac-­‐‑specific  promoter  to  express  this  transgene  specifically  in  the  fly  heart  
(Figure  5).    Each  of  these  components  are  described  in  detail  below:  
3.1.1.1  Constitutively  active  calcineurin  (CanAact)  
Calcineurin  acts  as  a  calcium/calmodulin-­‐‑dependent  protein  phosphatase.    The  
large  CanA  subunit  has  phosphatase  activity  and  consists  of  several  domains:  the  
catalytic  domain,  which  regulates  protein  dephosphorylation  [6],  the  CanB  binding  
domain  [7],  the  calcium/calmodulin  binding  domain,  and  the  autoinhibitory  domain  [8],  
summarized  in  Figure  5.    Binding  of  calcium/calmodulin  activates  calcineurin  by  
alleviating  autoinhibition.    A  constitutively  active  calcineurin  (CanAact)  was  generated  as  
previously  described,  using  Drosophila  cDNA,  amplifying  only  up  to  the  
calcium/calmodulin  binding  domain  and  eliminating  the  autoinhibitory  domain  [9-­‐‑11].    
This  results  in  a  protein  that  is  constitutively  active  by  alleviating  autoinhibition.  
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3.1.1.2  Tags  (YFP  or  Flag)  
I  generated  CanAact  according  to  previous  studies,  adding  either  a  YFP-­‐‑  or  a  Flag-­‐‑  
tag  to  the  N-­‐‑terminus  to  facilitate  detection  of  the  transgene  (Figure  5B-­‐‑C).    The  YFP  tag  
facilitates  convenient  visualization  of  the  transgene  using  fluorescence  microscopy  with  
the  possibility  of  the  larger  YFP  molecule  (238  aminio  acids,  26.4  kDa)  to  interfere  with  
or  exert  effects  independent  of  CanAact.    Of  note,  the  catalytic  activity  of  N-­‐‑terminal  YFP-­‐‑
tagged  CanAact  has  been  confirmed  in  studies  by  a  number  of  investigators,  using  well  
characterized  NFAT  reporter  assays  [205,  206],  NFAT  phosphorylation  assays  [205],  and  
NF-­‐‑κB  reporter  assays  [207].    In  contrast,  Flag  is  a  short  8  amino  acid  sequence  (1  kDa)  
that  is  less  likely  to  interfere  with  CanAact  activity  but  requires  additional  immuno-­‐‑
staining  techniques  for  detection.    Both  transgenic  flies  were  generated  and  analyzed  to  
rule  out  any  effects  that  may  result  from  the  interference  of  the  tag  or  transgene  
insertion  site.  
  
3.1.1.3  Cardiac-­‐‑specific  promoter  (tinC-­‐‑)  
In  order  to  create  a  Drosophila  line  expressing  CanAact  in  the  heart,  I  used  the  
tinC-­‐‑  promoter,  a  304  bp  intronic  region  within  the  tinman  gene  that  controls  cardiac-­‐‑
specific  gene  expression  in  conjunction  with  a  minimal  hsp70  promoter  (tinC-­‐‑CanAact)  
[189,  210,  211].      
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The  tinman  gene  is  a  key  regulatory  gene  for  all  mesodermal  development,  
including  that  of  the  heart,  visceral,  and  somatic  muscle.    Even  though  the  tinman  gene  
is  expressed  in  the  entire  mesoderm  at  early  stages  of  development,  by  stage  12,  
expression  is  confined  to  all  cardiac  muscle  cells,  excluding  the  sevenup  (svp)-­‐‑
expressing  ostia  cells.    This  expression  pattern  is  controlled  by  multiple  enhancer  
elements  in  the  tinman  gene.    The  enhancer  element  I  used  in  my  study,  tinC-­‐‑,  




Figure  5:  The  structure  of  calcineurin  and  CanAact  constructs.  













A)  Calcineurin (CanA)
B)  Cardiac-specific YFP-tagged constitutively active calcineurin 
      (tinC-YCanAact)
C)  Cardiac-specific Flag-tagged constitutively active calcineurin 
      (tinC-YCanAact)
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A)  Domain  structure  of  calcineurin  (CanA),  including  the  catalytic  domain  
(Catalytic),  the  CanB-­‐‑binding  domain  (B),  the  calmodulin-­‐‑binding  domain  (M),  and  the  
autoinhibitory  domain  (I).    B)  Domain  structure  of  the  YFP-­‐‑tagged  constitutively  active  
calcineurin  (tinC-­‐‑YCanAact)  construct,  excluding  the  autoinhibitory  domain  (I,  Figure  
5A),  inserting  a  premature  stop  codon,  and  showing  the  YFP  N-­‐‑terminal  tag  and  
cardiac-­‐‑specific  tinC-­‐‑  promoter.    C)  Domain  structure  of  the  Flag-­‐‑tagged  constitutively  
active  calcineurin  (tinC-­‐‑FCanAact)  construct.    (Referencing  [8].)  
  
3.1.2 Expression of cardiac-specific CanAact in the fly 
After  injecting  the  tinC-­‐‑YCanAact  construct  into  Drosophila  embryos,  identifying  
germline  transmission  of  the  transgene,  mapping  the  chromosomal  insertion,  and  
establishing  stable  stocks,  fluorescence  microscopy  was  used  to  confirm  expression  of  
the  transgene  (Figure  6).    Cardiac-­‐‑specific  YFP  is  detected  in  stage  16  embryos  and  1-­‐‑2  
day  old  adult  flies.    This  confirmed  that  the  transgene  was  expressed  as  expected  in  the  
fly  heart.    In  addition,  it  is  also  observed  that  the  fly  heart  is  already  visibly  larger  at  an  
embryonic  state.  
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Figure  6:  tinC-­‐‑YCanAact  fly  hearts  express  cardiac  YFP-­‐‑tagged  CanAact  and  are  
larger  than  tinC-­‐‑GFP  control  fly  hearts  
Confocal  microscopy  detecting  the  GFP  or  YFP  tag  in  stage  16  embryos  or  the  A1  
abdominal  segment  of  adult  flies  in  A,  C)  tinC-­‐‑GFP  or  B,  D)  tinC-­‐‑YCanAact  flies.    C,  D)  
Adult  flies  were  dissected  to  reveal  the  heart  from  the  ventral  side.    Images  detect  
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3.2 Expressing CanAact in the heart induced a cardiac 
enlargement phenotype 
After  the  CanAact-­‐‑expressing  fly,  lines  were  established,  multiple  methods  were  
employed  to  phenotype  cardiac  structure  and  function,  as  described  in  the  sections  
below.  
  
3.2.1 Optical coherence tomography (OCT)  
I  performed  optical  coherence  tomography  (OCT)  on  both  tinC-­‐‑YCanAact  and  
tinC-­‐‑FCanAact  flies.    This  allowed  for  real-­‐‑time  imaging  of  the  beating  heart  in  alive,  
awake  adult  flies.    Several  transgenic  lines  were  generated  and  tested  for  both  tinC-­‐‑
YCanAact  and  tinC-­‐‑FCanAact  insertions,  including  lines  where  the  transgenic  insertion  site  
was  mapped  to  the  first,  second,  or  third  chromosomes  (Figure  7A-­‐‑B).    Results  showed  
that  several  independent  transgenic  lines  induced  significant  cardiac  enlargement  
(increased  end-­‐‑diastolic  dimension).    In  addition  to  examining  end-­‐‑diastolic  dimension  
(EDD),  the  size  of  the  cardiac  chamber  at  its  most  relaxed  state,  fractional  shortening  
(FS)  was  also  calculated  as  a  measurement  of  cardiac  contractility  for  heterozygous  tinC-­‐‑
YCanAact  and  tinC-­‐‑FCanAact  flies.    Results  show  a  significant  increase  in  EDD  and  a  
significant  decrease  in  FS  in  both  tinC-­‐‑YCanAact  and  tinC-­‐‑FCanAact  flies,  signifying  that  
CanAact  in  the  heart  induces  the  cardiac  chamber  to  enlarge  and  cardiac  contractility  to  
decline  (Figure  7C-­‐‑D).    There  was  a  15%  decrease  in  fractional  shortening  in  CanAact  
flies.    In  humans,  normal  fractional  shortening  ranges  from  25-­‐‑45%,  where  a  15%  
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reduction  corresponds  to  severe  abnormality  [61].    All  further  screening  and  suppressor  
studies  were  of  flies  with  the  transgene  in  a  heterozygous  state.    
  
  
Figure  7:  CanAact  induced  cardiac  enlargement  and  decreased  contractility  
assayed  using  optical  coherence  tomography  (OCT)  
Quantitative  results  from  OCT  images  of  A)  homozygous  tinC-­‐‑YCanAact  and  B)  
tinC-­‐‑FCanAact  fly  hearts  compared  to  w1118  control.    Each  number  denotes  an  independent  
line  generated  from  embryo  injection  of  the  respective  constructs,  either  tinC-­‐‑YCanAact  or  
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C-­‐‑D)  Representative  OCT  images  and  quantitated  results  for  heterozygous  C)  tinC-­‐‑
YCanAact  or  D)  tinC-­‐‑FCanAact  flies  compared  to  w1118  control.    Expressing  either  YCanAact  
or  FCanAact  in  the  fly  heart  resulted  in  cardiac  enlargement  and  diminished  contractility.  
(*P<0.05,  **P<0.01,  ***P<0.001,  ****P<0.0001.  One-­‐‑way  ANOVA  with  Bonferroni  




Cardiac  enlargement  and  the  fly  heart  were  also  examined  more  closely  using  
paraffin  sectioning  and  hematoxylin  and  eosin  (H&E)  staining  (Figure  8).    Either  control  
(tinC-­‐‑GFP  or  w1118)  or  CanAact  (tinC-­‐‑YCanAact  or  tinC-­‐‑FCanAact)  flies  were  embedded  in  
paraffin,  sectioned  8µμm  thick,  and  stained  with  hematoxylin  and  eosin  (H&E).    Lumen  
area  and  perimeter  of  tinC-­‐‑CanAact  fly  hearts  were  significantly  enlarged  compared  to  
control.    Interestingly,  abnormalities  in  cardiac  wall  thickness  or  musculature  structure  
in  these  histological  sections  were  not  observed,  which  is  distinct  from  the  mouse  
phenotype  [9].    These  results  corroborate  the  feasibility  of  using  tinC-­‐‑CanAact  flies  as  a  
sensitized  line  for  genetic  screening.  
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Figure  8:  Histological  sections  showed  that  CanAact  induced  cardiac  
enlargement  
Histological  sections  from  paraffin  sectioning  and  hematoxylin  and  eosin  (H&E)  
staining  was  performed  on  homozygous  tinC-­‐‑YCanAact  or  tinC-­‐‑FCanAact  flies  (A).    Blue  
arrows  point  to  the  heart,  located  underneath  the  dorsal  abdominal  cuticle.    Quantitative  
analysis  with  multiple  images  was  performed  in  imageJ,  measuring  B)  heart  wall  
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YCanAact  flies.    CanAact  caused  significant  increase  in  cardiac  lumen  area  and  perimeter,  
but  not  cardiac  wall  thickness.  (*P<0.01;  **P<0.0001,  student  t  test.    Data  represent  mean  
±SEM.)  
  
3.3 CanAact-induced cardiac enlargement persisted with age 
I  also  examined  cardiac  enlargement  and  contractility  up  to  5  weeks  (35  days)  
post-­‐‑eclosion  (Figure  9).    As  the  results  show,  tinC-­‐‑FCanAact  flies  display  sustained  
cardiac  enlargement  and  decreased  contractility  compared  to  control  w1118  1  to  5  weeks  
after  eclosion.    Control  and  tinC-­‐‑FCanAact  flies  also  had  an  increase  in  end-­‐‑diastolic  
dimension  throughout  aging.    I  further  determined  whether  CanAact  induced  an  age-­‐‑
dependent  increase  in  cardiac  enlargement.    There  was  no  interaction  between  the  
control  and  CanAact  lines  by  ANOVA,  indicating  that  CanAact  did  not  exacerbate  the  rate  
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Control  w1118  or  tinC-­‐‑FCanAact  flies  were  collected  after  eclosion  and  assayed  using  
optical  coherence  tomography  (OCT).    Throughout  5  weeks  of  age,  tinC-­‐‑FCanAact  flies  
displayed  significant  cardiac  enlargement  (two-­‐‑way  ANOVA,  P<0.0001)  and  decreased  
contractility  (two-­‐‑way  ANNOVA,  P<0.0001).    End-­‐‑diastolic  dimension  increased  with  
age  (two-­‐‑way  ANOVA,  P<0.0001).    No  significant  interaction  was  detected  using  two-­‐‑
way  ANOVA,  indicating  that  the  cardiac  dimensions  enlarge  with  age,  but  CanAact  does  
not  increase  the  rate  of  enlargement.    (N=7-­‐‑17  in  each  group.)  
  
  
3.4 CanAact-induced cardiac enlargement was not due to 
increase in cell number 
To  further  analyze  the  nature  of  CanAact-­‐‑induced  cardiac  enlargement,  I  
examined  whether  the  increase  in  heart  size  was  a  result  of  increased  myocyte  number  
or  hypertrophy  of  individual  cells.    This  was  addressed  by  expressing  cardiac-­‐‑specific  
nuclear  RFP  (tinC-­‐‑Gal4>nuclear  RFP)  in  the  context  of  tinC-­‐‑GFP  or  tinC-­‐‑YCanAact  (Figure  
10).    The  number  of  cardiac  cells  present  in  the  abdominal  segments  A2  and  A3  was  not  
altered  in  tinC-­‐‑YCanAact  flies.  These  results  show  that  the  cardiac  enlargement  is  not  due  
to  proliferation.    Studies  to  directly  measure  individual  cell  size  will  provide  
quantitative  evidence  to  confirm  the  notion  that  cardiac  enlargement  involves  the  
increase  of  individual  cell  size.  
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Figure  10:  CanAact  fly  hearts  do  not  have  an  increased  number  of  cells.  
Nuclei  of  A)  control  tinC-­‐‑GFP/tinC-­‐‑Gal4>UAS-­‐‑nuclear  RFP  and  B)  tinC-­‐‑
YCanAact/tinC-­‐‑Gal4>UAS-­‐‑nuclear  RFP  flies.    Abdominal  segments  A1-­‐‑A3  were  
determined  by  presence  of  ostial  cells  and  the  pattern  of  the  dorsal  abdominal  cuticle.    
tinC-­‐‑GFP  and  tinC-­‐‑YCanAact  flies  both  have  4  cardiac  cells  in  the  A2-­‐‑A3  segments  apart  


















Chapter 4. Performing a deficiency screen using the 
tinC-CanAact fly as a sensitized line 
  
After  identifying  a  significant  phenotype  in  flies  that  expressed  cardiac-­‐‑specific  
CanAact,  I  tested  the  feasibility  of  using  the  tinC-­‐‑CanAact  fly  as  a  sensitized  line  to  perform  
genetic  screening.    The  approach  was  validated  by  examining  effects  of  a  known  
calcineurin  modifier,  Mef2.    Then,  a  deficiency  screen  was  performed  to  determine  a  
suppressor  region  containing  genes  that  modify  CanAact.    From  this  screen,  I  identified  
Galactokinase  as  a  novel  modifier  of  CanAact-­‐‑induced  cardiac  enlargement.  
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4.1 Deficiency of the known CanAact modifier, Mef2, suppressed 
CanAact-induced cardiac enlargement 
In  order  to  establish  the  feasibility  of  finding  a  modifier  of  the  heart  phenotype,  a  
known  downstream  regulator  of  calcineurin  signaling  [11,  61]  was  analyzed.    Two  main  
direct  targets  of  calcineurin  are  currently  known:  NFAT  and  Mef2.    Since  Drosophila  do  
not  express  the  NFAT  regulated  by  calcineurin  [80],  it  is  conceivable  that  a  main  
downstream  regulator  of  calcineurin  is  Mef2.    To  test  the  hypothesis  that  Mef2  was  
important  for  generating  a  cardiac  phenotype  downstream  of  CanAact,  the  cardiac  
phenotype  of  CanAact  was  examined  in  the  context  of  Mef2  deficiency.    The  tinC-­‐‑FCanAact  
line  was  used  as  a  sensitized  line  and  crossed  to  Df(2R)X1,Mef2X1  flies  (a  fly  line  that  is  
haploinsufficient  for  Mef2),  resulting  in  a  fly  with  half  the  normal  amount  of  Mef2.    
+/tinC-­‐‑FCanAact;+/Df(2R)X1,Mef2X1  flies  had  improved  chamber  dimensions  compared  to  
+/tinC-­‐‑FCanAact  (Figure  11),  demonstrating  that  deficiency  of  a  modifier  can  rescue  
cardiac  enlargement  of  the  sensitized  line.  
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Figure  11:  Deficiency  in  the  known  CanAact  modifier,  Mef2,  rescued  CanAact-­‐‑
induced  cardiac  enlargement.  
A-­‐‑D)  Representative  OCT  images  of  control  w1118,  heterozygous  +/tinC-­‐‑FCanAact,  
heterozygous  deficiency  in  +/Mef2  (Mef2X1),  and  heterozygous  +/tinC-­‐‑FCanAact;  +/Mef2X1.    
E,F)  Quantification  of  OCT  images  from  multiple  flies  of  E)  end-­‐‑diastolic  dimension  and  
F)  fractional  shortening.    Deficiency  in  Mef2  rescued  CanAact-­‐‑induced  cardiac  
enlargement.    (*P<0.05,  **P<0.01,  ***P<0.0001,  One-­‐‑way  ANOVA  with  Bonferroni  
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4.2 A deficiency screen determines a suppressor region that 
rescued CanAact-induced cardiac enlargement. 
Having  generated  a  sensitized  line  that  displays  a  significant  cardiac  
enlargement  phenotype,  a  deficiency  screen  was  performed,  starting  with  regions  
previously  identified  to  modify  phenotypes  from  CanAact  overexpression  in  the  eye  and  
mesoderm.  
4.2.1 Selecting a region to initiate deficiency screening 
Deficiency  stocks  cover  98.4%  of  the  Drosophila  euchromatic  genome  
(flystocks.bio.indiana.edu)  [212].    The  Bloomington  Drosophila  Stock  Center  offers  a  
deficiency  kit  composed  of  462  fly  stocks  that  cover  the  genetic  material  maximally.    The  
high  number  of  stocks  calls  for  the  need  to  prioritize  a  region  to  start  screening.    In  order  
to  maximize  the  probability  of  discovering  a  novel  modifier  gene,  I  referenced  two  
previous  screens  for  modifiers  of  CanAact  [10,  11].  
Previously,  two  independent  screens  had  been  conducted  to  identify  modifiers  of  
calcineurin  phenotypes  in  tissues  other  than  the  heart  [10,  11].    The  suppressor  regions  
from  these  two  studies  are  summarized  in  Table  1.    Sullivan  and  Rubin  performed  a  
dominant  modifier  screen  in  the  Drosophila  eye  and  found  five  suppressor  and  four  
enhancer  loci  [10].    Gajewski  et  al  found  seven  different  deletion  intervals  that  
suppressed  the  lethal  phenotype  of  constitutively  active  calcineurin  driven  by  the  
general  mesodermal  driver  24B  [11].    Importantly,  only  one  interval  overlapped  between  
these  two  studies  on  chromosome  3L,  cytolocation  66F,  emphasized  in  gray  shading  in  
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Table  1.    Therefore,  I  initiated  a  deficiency  screen  to  identify  modifiers  of  CanAact-­‐‑




4.2.2 A deficiency screen reveals a suppressor region for CanAact-
induced cardiac enlargement  
I  initiated  a  deficiency  screen  according  to  the  overlapping  region  between  the  
Sullivan  and  Rubin  and  Gajewski  et  al.  screens  described  in  the  previous  section.    Eight  
deficiency  lines  were  obtained  from  the  Bloomington  Drosophila  Stock  Center  (Figure  
12A).    All  deficiency  lines  were  crossed  to  either  w1118  control  or  tinC-­‐‑YCanAact  flies.    
Using  optical  coherence  tomography  (OCT)  to  determine  end-­‐‑diastolic  dimension  (EDD)  
and  fractional  shortening  (FS),  I  compared  these  cardiac  dimensions  between  control  
w1118,  the  sensitized  line  heterozygous  tinC-­‐‑YCanAact,  the  heterozygous  deficiency  alone,  
and  tinC-­‐‑YCanAact  in  the  context  of  a  heterozygous  deficiency.    If  the  region  
encompassed  by  a  deficiency  line  included  a  gene  that  influences  any  step  downstream  
of  calcineurin  activation,  presence  of  the  deficiency  will  rescue  the  tinC-­‐‑YCanAact  
phenotype.    Out  of  the  8  lines  screened,  only  two,  Df(3L)ED4416  and  Df(3L)BSC130,  
modified  CanAact-­‐‑induced  cardiac  enlargement  (Figure  12B-­‐‑C).    One  of  the  deficiency  
lines,  Df(3L)ED4421,  displayed  cardiac  enlargement  alone  without  CanAact  and  was  not  
included  in  determining  the  suppressor  region  (Figure  12C).    Delineated  from  these  
     60  
results,  I  determined  a  region  in  between  the  two  dotted  lines  (Figure  12A)  which  
contains  a  gene  that  modifies  CanAact-­‐‑induced  cardiac  enlargement.    This  region  spans  a  
total  of  13  genes  as  shown  in  the  expanded  view  in  Figure  12A.  
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A)  Genetic  map  of  deficiency  stocks  tested  and  depiction  of  the  chromosomal  
region  that  rescues  CanAact-­‐‑induced  cardiac  enlargement.  (Adapted  from  Gbrowse,  
http://flybase.org/cgi-­‐‑bin/gbrowse/dmel).    Dotted  lines  indicate  the  suppressor  region.    
Genes  within  the  suppressor  region  are  shown  in  the  magnified  view  below.    (Green  
bars=  rescuing  deficiencies.    Red  bars=  non-­‐‑rescuing  deficiencies.    Black  bar=  deficiency  
that  causes  cardiomyopathy  on  its  own.)    (B-­‐‑C)  Summary  data  for  end-­‐‑diastolic  
dimensions  and  fractional  shortenings  of  tinC-­‐‑YCanAact  alone  and  in  the  context  of  
molecularly-­‐‑defined  genomic  deficiencies  shown  in  (A).    All  deficiencies  were  tested  in  
the  heterozygous  states.    Two  deficiency  lines  rescued  the  tinC-­‐‑YCanAact  phenotype,  
Df(3L)ED4416  and  Df(3L)BSC130,  narrowing  down  the  original  suppressor  region  to  the  
region  in  between  the  dotted  lines  in  (A).  C)  End-­‐‑diastolic  dimensions  and  fractional  
shortenings  for  w1118  control,  tinC-­‐‑YCanAact,  or  Drosophila  lines  utilized  in  the  deficiency  
screen  without  YCanAact.    Note  that  Df(3L)ED4421  covers  the  deficiency  region  but  was  
dilated  on  its  own  without  CanAact  expression,  and  was  not  considered  in  defining  the  
deficiency  region.    (One-­‐‑way  ANOVA  with  Bonferroni  correction.    *P<0.01,  **P<0.0001.    
Data  represent  mean  ±SEM.)  
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4.3 Using RNAi or transposable element insertion stocks to 
determine the causal genes in the suppressor region 
Results  in  the  previous  section  determined  a  suppressor  region  which  
encompassed  genes  that  modulate  CanAact-­‐‑induced  cardiac  enlargement.    There  are  13  
genes  in  this  region;  Table  2  outlines  the  properties  of  these  genes  (flybase.org,  
flyatlas.org).    Out  of  these  genes,  a  couple  stood  out:  1)  the  dorsocross  (Doc)  genes,  
Doc1,  Doc2,  and  Doc3  are  known  to  regulate  cardiac  development;  2)  galactokinase  
(Galk)  and  arginine  kinase  (Argk)  have  high  expression  in  the  adult  fly  heart.    
Subsequent  studies  followed  accordingly  to  determine  the  causative  modifier  gene  
within  the  smaller  region  identified.  
  
Table  2:  Genes  within  the  suppressor  region  
Gene   Possible  function   Human  orthologue   Expression  in  adult  heart  
CG5644   CHK  kinase-­‐‑like   none   Unknown  
CG13314   unknown   none   Unknown  
CG5288   galactokinase  
activity.  
galactokinase  2   High  
CG5068   catalytic  activity.   protein  phosphatase  
methylesterase  1  
No  
smg   protein  binding;  
translation  repressor  
activity  
none   Low  
CG5087   ubiquitin-­‐‑protein  
ligase  activity.  
ubiquitin  protein  ligase  
E3B  
Low  
Doc3   transcription  factor  
activity,  cardiac  
development  
T-­‐‑box  6   Low  
Doc2   transcription  factor  
activity,  cardiac  
none   No  
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development  
Doc1   transcription  factor  
activity,  cardiac  
development  
T-­‐‑box  6   No  
CG5144   arginine  kinase  
activity.  
none   No  
Argk   arginine  kinase  
activity.  
none   High  
CG4911   unknown   F-­‐‑box  protein  33   No  




Gene  information  obtained  from  flybase.org;  gene  expression  obtained  from  flyatlas.org.  
4.3.1 The dorsocross (Doc) genes 
There  are  three  dorsocross  genes,  Doc1,  Doc2  and  Doc3.    The  Doc  genes  are  
required  for  specification  of  cardioblasts  during  cardiac  development.    Cardioblasts  and  
pericardial  cells  do  not  form  in  embryos  with  a  deletion  of  all  three  Doc  genes  and  
overexpressing  Doc2  induces  ectopic  cardioblast  specification.    In  addition,  Doc  genes  
interact  with  the  cardiac  developmental  genes  tinman  (tin,  mammalian  Nkx-­‐‑2.5  protein)  
and  pannier  (pnr,  mammalian  Gata  protein)  during  cardiac  specification  [213].  Doc  genes  
have  been  implicated  in  the  regulation  of  cardiac  specification  by  maintaining  tin  
expression  and  activating  pnr.    Due  to  the  regulation  of  cardiac  development  by  Doc  
genes,  it  is  plausible  that  the  causal  gene  in  the  CanAact  cardiac  enlargement  suppressor  
region  may  be  a  Doc  gene.  
I  examined  the  Doc  genes  in  the  context  of  the  CanAact-­‐‑induced  cardiac  
enlargement  phenotype.    I  made  a  fly  that  expressed  tinC-­‐‑FCanAact  and  tinC-­‐‑Gal4  
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through  genetic  recombination  and  then  crossed  this  fly  line  with  flies  that  expressed  
RNAi  to  Doc1  (P{GD4334}v16746  and  P{TRiP.JF02222}),  Doc2  (P{GD4335}v37634),  or  Doc3  
(P{TRiP.JF02223}attP2).    The  knock-­‐‑down  of  Doc2  or  Doc3  genes  caused  cardiac  
enlargement  independent  of  CanAact  expression.    Furthermore,  CanAact-­‐‑induced  cardiac  
enlargement  was  not  rescued  in  the  context  of  RNAi  to  Doc  genes  (Figure  13).    These  
results  suggested  that  the  Doc  genes  were  not  responsible  for  the  suppression  of  CanAact-­‐‑
induced  cardiac  enlargement.  
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Figure  13:  Knocking  down  the  dorsocross  genes  did  not  rescue  CanAact-­‐‑induced  
cardiac  enlargement.  
Summary  data  of  end-­‐‑diastolic  dimensions  and  fractional  shortenings  for  w1118  
control,  heterozygous  tinC-­‐‑FCanAact  or  fly  lines  expressing  the  corresponding  RNAi  to  
dorsocross  (Doc)  genes.    Knocking  down  Doc2  and  Doc3  genes  caused  cardiac  
enlargement,  and  did  not  rescue  tinC-­‐‑FCanAact-­‐‑induced  cardiac  enlargement.    Doc1v16746  
tinC-Gal4   -     -     +     +    +    +     +    +    +    +           
Doc1v16747 RNAi   -     -     +     +     -     -     -     -     -     -       
Doc1JF02222 RNAi   -     -      -     -     +    +     -     -     -     -      
Doc2v37634 RNAi -     -     -     -      -     -     +    +     -     -        
Doc3JF02223 RNAi -     -     -     -      -     -     -     -     +     +      
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RNAi=  P{GD4334}v16746;  Doc1JF02222  RNAi=  P{TRiP.JF02222};  Doc2v37634  RNAi=  
P{GD4335}v37634;  Doc3JF02223  RNAi=  P{TRiP.JF02223}attP2.    All  transgenes  were  
heterozygous.    (*p<0.05,  **P<0.01,  ***P<0.001,  ****P<0.0001  compared  to  control  w1118.    
End-­‐‑diastolic  dimension  and  fractional  shortening  of  flies  expressing  RNAi  to  the  Doc  
genes  were  not  significantly  different  from  tinC-­‐‑FCanAact  flies.    These  results  indicate  that  
Doc  did  not  modify  CanAact-­‐‑induced  cardiac  enlargement.    One-­‐‑way  ANOVA  with  
Bonferroni  correction  for  multiple  comparisons.    Data  represent  mean  ±SEM.)  
  
  
4.3.2 Arginine kinase (Argk) 
Arginine  kinase  (Argk)  was  one  of  the  genes  highly  expressed  in  the  adult  fly  heart  
according  to  FlyAtlas  (Table  2).    Therefore,  I  examined  how  the  disruption  of  Argk  
would  influence  tinC-­‐‑YCanAact-­‐‑induced  cardiac  enlargement.    I  used  the  piggyback  
insertion  in  Argk,  PBac{PB}Argkf05255.    Results  from  OCT  imaging  show  that  disruption  of  
Argk  did  not  rescue  tinC-­‐‑YCanAact-­‐‑induced  cardiac  enlargement  (Figure  14),  suggesting  
that  Argk  is  not  the  causal  phenotype  in  the  deficiency  region.    However,  the  disruption  
only  caused  30%  reduction  in  gene  expression  and  protein  expression  was  not  tested.    It  
is  possible  that  the  lack  of  modification  by  disruption  of  ArgK  was  due  to  incomplete  
knock-­‐‑down  of  expression.  
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Figure  14:  Transposable  element  insertion  in  Argk  did  not  suppress  CanAact-­‐‑
induced  cardiac  enlargement.  
A)  End-­‐‑diastolic  dimensions  and  B)  fractional  shortenings  quantified  from  OCT  
m-­‐‑mode  images  of  control  w1118,  heterozygous  tinC-­‐‑YCanAact,  heterozygous  
PBac{PB}Argkf05255,  or  heterozygous  PBac{PB}Argkf05255  in  the  context  of  tinC-­‐‑YCanAact.    
PBac{PB}Argkf05255  insertion  in  Argk  did  not  rescue  tinC-­‐‑YCanAact-­‐‑induced  cardiac  
enlargement.    (*P<0.05;  **P<0.01;  ***P<0.0001,  one-­‐‑way  ANOVA  with  Bonferroni  
correction  for  multiple  comparisons.)    C)  Real-­‐‑time  RT-­‐‑PCR  of  Argk  expression  in  flies  
heterozygous  for  the  piggyback  insertion  in  Argk,  PBac{PB}Argkf05255.    Expression  level  of  
Argk  is  downregulated  in  PBac{PB}Argkf05255  flies.    (*P<0.05,  student’s  t  test.    All  data  
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4.3.3 Galactokinase (Galk) 
Galactokinase  (Galk)  was  another  one  of  the  genes  highly  expressed  in  the  adult  fly  
heart  according  to  FlyAtlas  (Table  2).    Galk  phosphorylates  galactose  and  N-­‐‑acetyl-­‐‑
galactosamine  (Galactose/GalNAc),  allowing  further  utilization  in  either  metabolism  
(energy  production)  or  glycosylation  (protein  modification)  [214].    To  date,  no  studies  
have  directly  investigated  the  function  of  Galk  in  the  heart.  
  
4.3.3.1  Transposable  elements  in  Galk  rescue  tinC-­‐‑YCanAact-­‐‑induced  cardiac  
enlargement  
I  tested  the  hypothesis  that  Galk  was  the  causative  modifier  in  the  suppressor  
region  for  CanAact  cardiac  enlargement.    I  obtained  flies  with  transposable  element  
insertions  in  Galk  (PBac{PB}Galkc03848  and  Mi{ET1}GalkMB10638)  and  analyzed  the  effect  of  
having  a  heterozygous  transposable  element  allele  in  the  context  of  tinC-­‐‑YCanAact.    
Results  show  that  both  transposable  elements  in  Galk  rescued  the  CanAact-­‐‑induced  
cardiac  contractility  phenotype  (Figure  15A-­‐‑B).    Mi{ET1}GalkMB10638  rescued  both  end-­‐‑
diastolic  dimension  and  fractional  shortening  while  PBac{PB}Galkc03848  rescued  the  
fractional  shortening  to  a  lesser  extent  and  did  not  significantly  rescue  increased  end-­‐‑
diastolic  dimension.    This  may  be  due  to  the  lesser  extent  of  gene  knock-­‐‑down  as  shown  
with  real-­‐‑time  RT-­‐‑PCR  (Figure  15C).    These  results  show  that  transposable  elements  in  
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Figure  15:  Transposable  elements  in  galactokinase  rescued  CanAact-­‐‑induced  
cardiac  enlargement.  
(A-­‐‑B)  Summary  data  for  (A)  end-­‐‑diastolic  dimensions  and  (B)  fractional  
shortenings  of  flies  expressing  w1118  control,  heterozygous  tinC-­‐‑YCanAact,  the  
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Mi{ET1}GalkMB10638  (Mi{ET1}Galkrev),  in  the  context  of  tinC-­‐‑YCanAact.    The  two  transposable  
elements  in  Galk  rescued  tinC-­‐‑YCanAact  -­‐‑mediated  cardiac  contractility,  Mi{ET1}GalkMB10638  
rescued  cardiac  enlargement,  while  a  precise  excision  reverted  the  rescue.    (A:  *P<0.05,  
**P<0.01;  B:  *P<0.05,  **P<0.001,  ***P<0.0001  compared  to  tinC-­‐‑YCanAact  or  
Mi{ET1}GalkMB10638  as  indicated  with  an  over  bar.)  (C)  qRT-­‐‑PCR  for  Galk  expression  of  
w1118  control,  homozygous  PBac{PB}Galkc03848,  or  homozygous  Mi{ET1}GalkMB10638.    Galk  
expression  is  downregulated  by  transposable  element  insertions  (*P<0.001  compared  to  
w1118  control).    (D)  qRT-­‐‑PCR  of  Galk  expression  in  w1118  control  flies,  flies  heterozygous  
for  tinC-­‐‑YCanAact  alone,  in  the  context  of  heterozygous  Mi{ET1}GalkMB10638,  or  a  precise  
excision  of  Mi{ET1}GalkMB10638,  Mi{ET1}Galkrev  (*P<0.05,  **P<0.001  compared  to  
heterozygous  tinC-­‐‑YCanAact/Mi{ET1}GalkMB10638).    One-­‐‑way  ANOVA  with  Bonferroni  
correction  for  multiple  comparisons,  all  data  represent  mean  ±SEM.  
  
  
4.3.3.2  RNAi  to  Galk  rescued  tinC-­‐‑YCanAact-­‐‑induced  cardiac  enlargement  
To  further  confirm  that  the  tinC-­‐‑CanAact  cardiac  phenotype  is  rescued  by  
deficiency  of  Galk  instead  of  non-­‐‑target  effects  from  transposable  elements,  flies  
expressing  RNAi  against  Galk  were  utilized.    Drosophila  expressing  shRNA  that  is  
converted  into  siRNA  by  Dicer  protein  to  degrade  Galk  mRNA  was  used  
(P{KK107801}VIE-­‐‑260B).    Control  w1118,  driver  alone,  RNAi  transgene  no  driver,  RNAi  
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expression  alone,  tinC-­‐‑YCanAact  alone,  or  Galk  RNAi  rescue  of  tinC-­‐‑YCanAact  were  
generated  according  to  the  crosses  in  Figure  16A.    Results  show  that  RNAi  to  Galk  
rescued  tinC-­‐‑YCanAact-­‐‑induced  cardiac  enlargement  and  driver  alone,  RNAi  transgene  
alone,  and  RNAi  expression  alone  controls  did  not  cause  a  cardiac  phenotype  (Figure  
16B-­‐‑C).    Real-­‐‑time  RT-­‐‑PCR  confirmed  that  gene  expression  was  knocked  down  in  RNAi  
expressing  flies  (Figure  16D).    These  results  further  confirm  that  deficiency  of  Galk  
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A)  Experimental  design  of  fly  crosses  set  up  for  RNAi  rescue  experiment.    B)  
End-­‐‑diastolic  dimensions  and  C)  fractional  shortenings  from  OCT  m-­‐‑mode  images  of  F1  
progeny  from  the  crosses  made  in  (A).    Compared  to  control  w1118,  driver  or  RNAi  alone  
do  not  result  in  an  enlargement  phenotype  and  expressing  RNAi  rescued  the  tinC-­‐‑
YCanAact  cardiac  enlargement  phenotype.    (*P<0.05,  **P<0.001,  ***P<0.0001,  one-­‐‑way  
ANOVA  with  Bonferroni  correction.)    D)  Real-­‐‑time  RT-­‐‑PCR  confirmed  that  Galk  mRNA  
levels  were  down-­‐‑regulated  in  flies  expressing  Galk  RNAi.    (*P<0.001,  student’s  t  test.    
All  data  represent  mean  ±SEM.)     





Chapter 5. Characterizing galactokinase (Galk) as a 
modifier of CanAact-induced cardiac enlargement 
Results  in  the  previous  chapter  established  a  suppressor  region  which  
encompasses  genes  that  modify  CanAact-­‐‑induced  cardiac  enlargement  and  revealed  
galactokinase  (Galk)  as  a  potential  modifier.    I  proceeded  to  further  characterize  this  novel  
finding  using  the  tinC-­‐‑Gal4>UAS-­‐‑CanAact  fly  as  a  model.    I  used  multiple  driver  lines  to  
express  UAS-­‐‑CanAact  in  different  tissues  and  analyzed  additional  phenotypes  including  
life  span,  wing,  and  lethality.    In  addition,  I  examined  the  effect  of  knocking  down  
mammalian  Galk  orthologues  on  calcineurin  signaling  using  siRNA  in  cell  culture.  
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5.1 Deficiency in Galk also rescued tinC-Gal4>UAS-YCanAact-
induced phenotypes 
I  had  used  multiple  methods  to  confirm  that  deficiency  of  Galk  rescued  the  tinC-­‐‑
YCanAact-­‐‑induced  cardiac  enlargement  phenotype.    I  generated  another  UAS-­‐‑YCanAact  fly  
to  utilize  the  Gal4/UAS  system  for  two  main  purposes:  1)  to  further  demonstrate  that  
deficiency  of  Galk  rescues  CanAact-­‐‑induced  cardiac  enlargement  using  another  system;  
and  2)  to  examine  the  effect  of  Galk  deficiency  in  other  tissues.    This  first  section  
describes  the  phenotype  of  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  and  rescue  by  deficiency  of  Galk.  
  
5.1.1 The tinC-Gal4>UAS-YCanAact fly displayed cardiac enlargement 
that was rescued by deficiencies encompassing Galk and known 
modifiers of calcineurin signaling 
The  UAS-­‐‑YCanAact  line  was  crossed  with  a  tinC-­‐‑Gal4  line  to  express  YCanAact  in  
the  heart.    Cardiac  enlargement  was  also  displayed  in  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  flies:  end-­‐‑
diastolic  dimension  was  enlarged  and  fractional  shortening  was  decreased  (Figure  17).    
In  the  context  of  tinC-­‐‑Gal4>UAS-­‐‑YCanAact,  the  deficiencies  incorporating  Galk  previously  
found  to  rescue  tinC-­‐‑YCanAact-­‐‑induced  cardiac  enlargement  (Df(3L)ED4416  and  
Df(3L)BSC130)  also  rescued  cardiac  enlargement,  further  demonstrating  Galk  deficiency  
as  a  suppressor  of  CanAact-­‐‑induced  cardiac  enlargement.    In  addition,  known  modifiers  
of  CanAact  (Mef2,  sprouty,  and  CanB2)  were  tested  for  rescue  of  the  cardiac  enlargement  
phenotype  to  assay  the  consistency  of  the  system  for  detecting  modifiers.    Deficiency  of  
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Mef2  (Df(2R)X1,Mef2X1),  sprouty  (styΔ5),  and  CanB2  (P{EP}CanB2EP774),  also  rescued  tinC-­‐‑




Figure  17:  Deficiency  of  Galk  also  rescued  tinC-­‐‑Gal4>UAS-­‐‑YCanAact-­‐‑induced  
cardiac  enlargement.  
A)  End-­‐‑diastolic  dimensions  and  B)  fractional  shortenings  for  w1118  control  (first  
column),  UAS-­‐‑YCanAact  alone  (no  driver),  tinC-­‐‑Gal4  alone  (driver  only),  tinC-­‐‑Gal4>UAS-­‐‑
YCanAact  (CanAact  only),  and  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  in  the  context  of  deficiencies  in  the  
known  calcineurin  modifiers:  Mef2,  sprouty,  or  CanB2,  or  the  deficiencies  encompassing  
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Gal4>UAS-­‐‑YCanAact  also  induced  a  significant  cardiac  enlargement  phenotype.    This  is  
rescued  by  the  known  modifiers  of  calcineurin:  Mef2,  sprouty,  and  CanB2,  and  
deficiencies  encompassing  Galk:  Df(3L)ED4416  and  Df(3L)BSC130.  (*P<0.05,  **P<0.01,  




5.1.2 The tinC-Gal4>UAS-YCanAact fly displayed thickening of the 
cardiac chamber wall that is rescued by disruption of Galk 
To  further  characterize  the  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  fly,  histology  of  the  fly  hearts  
was  examined.    Examining  the  hearts  of  tinC-­‐‑Gal4  (driver  alone)  or  tinC-­‐‑Gal4>UAS-­‐‑
YCanAact  flies  in  histological  sections,  wall  thickness  was  significantly  increased  in  tinC-­‐‑
Gal4>UAS-­‐‑YCanAact  flies  (Figure  18).    This  was  consistent  with  the  cardiac  hypertrophy  
observed  in  mice;  though  distinct  from  the  tinC-­‐‑YCanAact  phenotype  which  displayed  
cardiac  enlargement  without  a  thickening  of  the  cardiac  chamber  wall.    The  higher  
expression  level  of  CanAact  with  the  Gal4/UAS  bipartite  system  may  have  caused  
sarcomeric  structures  to  be  added  in  parallel  as  well  as  in  series.    The  effect  of  disrupting  
Galk  with  Mi{ET1}GalkMB10638  was  also  examined  for  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  flies.    
Results  showed  that  disruption  of  Galk  with  Mi{ET1}GalkMB10638  rescued  the  increase  in  
wall  thickness  induced  by  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  (Figure  18).  
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Figure  18:  Wall  thickness  is  increased  in  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  fly  hearts  and  is  
rescued  by  disruption  of  Galk.  
A)    Paraffin  sections  8µμm  thick  with  H&E  stain  for  tinC-­‐‑Gal4  (driver  alone),  tinC-­‐‑
Gal4>UAS-­‐‑YCanAact,  or  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  in  the  context  of  Mi{ET1}GalkMB10638  
(Mi{ET1}Galk)  flies.    Arrow  heads  point  to  the  heart  wall.    B)  Quantitative  results  
measured  from  images  of  histological  sections  in  image  J.    Measurements  were  made  
from  the  dorsal,  ventral,  left  and  right  of  the  heart,  excluding  the  dorsal  longitudinal  
muscle  underlying  the  heart  tube.    Compared  to  control  flies,  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  
flies  display  a  significantly  thicker  heart  wall  which  is  rescued  in  the  context  of  
Mi{ET1}GalkMB10638.    (*P<0.05,  one-­‐‑way  ANOVA  with  Bonferroni  correction,  data  














tinC-Gal4      tinC-Gal4>UAS-YCanAact    tinC-Gal4>UASYCanAact
















N=    8      13      6 
     78  
  
5.2 Deficiency in Galk also rescued decreased life span of tinC-
YCanAact flies 
I  further  characterized  the  nature  of  the  Galk  disruption-­‐‑mediated  rescue  of  tinC-­‐‑
YCanAact  phenotypes.  The  life  span  of  tinC-­‐‑YCanAact  flies  relative  to  control  was  
examined.    Compared  to  flies  only  expressing  a  transposable  element  in  Galk,  
Mi{ET1}GalkMB10638,  which  displayed  a  normal  end-­‐‑diastolic  dimension  and  fractional  
shortening,  tinC-­‐‑YCanAact  flies  displayed  a  much  shorter  life  span,  with  98%  of  the  
progeny  not  surviving  past  80  days  post-­‐‑eclosion.    tinC-­‐‑CanAact  in  the  context  of  
Mi{ET1}GalkMB10638  rescued  this  shortening  of  life  span  (Figure  19).    These  results  show  
that  rescuing  cardiac  function  in  cardiac-­‐‑CanAact  flies  also  rescued  survival.    However,  a  





Figure  19:  Transposable  element  insertion  in  Galk  rescued  tinC-­‐‑YCanAact-­‐‑
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Survival  curve  of  male  and  female  flies  heterozygous  for  Mi{ET1}GalkMB10638,  tinC-­‐‑
YCanAact,  or  Mi{ET1}GalkMB10638  in  the  context  of  tinC-­‐‑YCanAact.    Mi{ET1}GalkMB10638  
significantly  rescued  the  tinC-­‐‑YCanAact  survival  phenotype.  (P<0.0001  for  both  male  and  
female  groups  comparing  tinC-­‐‑YCanAact  with  tinC-­‐‑YCanAact/Mi{ET1}GalkMB10638,  Mantel-­‐‑
Cox  log  rank  test.    N=60  in  each  group.)  
  
  
5.3 Disruption of Galk does not rescue cardiac enlargement of 
hdp2 flies. 
I  then  tested  whether  Mi{ET1}GalkMB10638  could  rescue  a  non  calcineurin-­‐‑mediated  
cardiomyopathy  of  the  troponin  I  mutant  (hdp2)  that  shows  a  flight  muscle  abnormality  
and  cardiac  dilation  [189,  203].    Mi{ET1}GalkMB10638  did  not  rescue  the  cardiac  dilation  
phenotype  of  heterozygous  hdp2  flies  (Figure  20),  indicating  that  Galk  involvement  is  
specific  to  CanAact-­‐‑induced  cardiomyopathy.  
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Figure  20:  Disruption  of  Galk  did  not  rescue  cardiac  enlargement  of  hdp2  flies  
Quantified  results  from  OCT  m-­‐‑mode  images  of  end-­‐‑diastolic  dimension,  end-­‐‑
systolic  dimensions,  and  fractional  shortenings  of  w1118  control,  heterozygous  hdp2  
(+/hdp2),  heterozygous  Mi{ET1}GalkMB10638  (+/Mi{ET1}Galk),  and  hdp2  in  the  context  of  
Mi{ET1}GalkMB10638  (+/hdp2;+/Mi{ET1}Galk).    Heterozygous  hdp2  induced  a  mild  cardiac  
enlargement  phenotype  that  was  not  rescued  by  Mi{ET1}GalkMB10638.    hdp2  is  a  fly  with  a  
null  mutation  of  troponin  I.    *P<0.05,  **P<0.01,  one-­‐‑way  ANOVA  with  Bonferroni  
correction.    All  data  represent  mean  ±SEM.  
  
  
5.4 Galk is not sufficient to induce cardiac enlargement. 
I  further  characterized  the  nature  of  Galk  in  the  heart  by  engineering  a  fly  to  
overexpress  Galk  in  the  heart.    A  transgenic  fly  was  made  expressing  UAS-­‐‑Galk.    This  
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cardiac  enlargement.    Compared  to  controls,  tinC-­‐‑YCanAact  fly  hearts  were  enlarged  
measuring  OCT  images  for  end-­‐‑diastolic  dimension  and  fractional  shortening  while  
tinC-­‐‑Gal4>UAS-­‐‑Galk  fly  hearts  are  not  (Figure  21).    These  results  indicate  that  expressing  
Galk  is  not  sufficient  to  induce  cardiac  enlargement  without  CanAact.  
  
  
Figure  21:  Overexpressing  Galk  in  the  fly  heart  did  not  induce  cardiac  
enlargement.  
A)  Quantification  for  m-­‐‑mode  OCT  images  measuring  end-­‐‑diastolic  dimensions  
and  fractional  shortenings  in  control  w1118,  heterozygous  tinC-­‐‑YCanAact,  tinC-­‐‑Gal4  (driver  
alone),  UAS-­‐‑Galk  (no  driver),  or  flies  expressing  tinC-­‐‑Gal4>UAS-­‐‑Galk.    Expressing  Galk  
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**P<0.0001  compared  to  control,  one-­‐‑way  ANOVA  with  Bonferroni  correction.)    B)  
Western  blots  demonstrating  expression  of  HA-­‐‑tagged  Galk  in  w1118  and  heterozygous  
Mef2-­‐‑Gal4>UAS-­‐‑Galk  flies.    Tubulin  is  used  as  an  internal  control.  
  
5.5 Galk modified expression of UAS-CanAact in a tissue-specific 
manner 
I  expressed  UAS-­‐‑YCanAact  in  different  tissues  including  ectoderm,  mesoderm,  
and  posterior  compartment  of  the  imaginal  wing  disc,  using  corresponding  -­‐‑Gal4  driver  
lines  to  further  characterize  the  nature  of  the  Galk  rescue  of  YCanAact  phenotypes  outside  
of  the  heart.      
  
5.5.1 Genetic disruption of Galk rescued e16E>UAS-YCanAact-induced 
wing vein abnormality  
According  to  previous  studies,  driving  CanAact  in  the  wing  with  an  engrailed  
driver  causes  wing  vein  abnormality  [10].    UAS-­‐‑YCanAact  expressed  under  the  control  of  
an  e16E-­‐‑Gal4  engrailed  driver  produced  a  variable  wing  vein  phenotype:  abnormality  in  
the  posterior  crossveins  (PCV)  and  the  longitudinal  wing  vein  L5  (Figure  22).    
Df(3L)ED4416  and  Mi{ET1}GalkMB10638  significantly  rescued  the  e16E-­‐‑Gal4>UAS-­‐‑YCanAact-­‐‑
induced  abnormal  wing  vein  phenotype.    The  percentage  of  normal  wing  vein  flies  
significantly  increased  from  11%  to  44%,  and  the  percentage  of  flies  with  abnormal  wing  
vein  phenotypes  decreased  from  89%  to  56%  with  a  genetic  deficiency  encompassing  
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Galk.    The  rescue  with  Mi{ET1}GalkMB10638  was  significant  but  less  pronounced,  with  an  
increase  of  5%  normal  to  31%  normal  wing  vein  flies,  and  a  decrease  of  95%  to  69%  
abnormal  wing  vein  flies  (Figure  22).    This  difference  could  be  explained  by  residual  
expression  of  Galk  in  the  Minos  insertion  mutant  or  interference  by  other  genes  within  
the  deficiency  region.  
  
  
Figure  22:  Disruption  of  Galk  rescued  e16E>UAS-­‐‑YCanAact-­‐‑induced  wing  vein  
abnormality.  
CanAact-induced wing vein phenotype
Percent progeny from
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Wings  of  progeny  from  the  cross  e16E-­‐‑Gal4  x  UAS-­‐‑
YCanAact/CyO;Df(3L)ED4416/MKRS.    Homozygous  e16E-­‐‑Gal4  (driver  only),  or  wings  of  
flies  expressing  e16E-­‐‑Gal4>UAS-­‐‑YCanAact  were  imaged.    A  range  of  phenotypes  were  
observed  in  flies:  normal,  abnormality  of  the  posterior  cross  vein  (PCV),  or  abnormality  
of  both  the  PCV  and  longitudinal  wing  vein  5  (L5).    Bar  graphs  on  the  right  show  
percentages  of  flies  displaying  the  corresponding  wing  vein  phenotypes.    Results  show  
that  genetic  deficiency  or  disruption  of  Galk  by  Df(3L)ED4416  or  Mi{ET1}GalkMB10638  
significantly  rescued  the  wing  vein  phenotype.  (*P<0.0001,  Fisher’s  exact  test  comparing  
percentage  of  normal  versus  abnormal  winged  flies.)  
  
5.5.2 Deficiency of Galk did not rescue Act5C-Gal4>UAS-YCanAact-
induced lethality  
The  effect  of  driving  UAS-­‐‑YCanAact  ubiquitously  with  the  Act5C-­‐‑Gal4  driver  was  
evaluated.    Ubiquitous  Act5C-­‐‑Gal4>UAS-­‐‑YCanAact  caused  lethality.    These  flies  died  at  
the  1st  instar  larval  stage.    Progeny  from  the  cross  Act5C-­‐‑Gal4/CyO  x  
YCanAact/CyO;Df(3L)ED4416/TM2  was  analyzed.    Since  Act5C-­‐‑Gal4>UAS-­‐‑YCanAact  caused  
lethality,  if  progeny  was  produced  in  the  context  of  Df(3L)ED4416,  this  would  signify  a  
rescue.    However,  results  showed  that  out  of  324  total  progeny,  no  flies  were  detected  
either  with  or  without  the  deficiency.    This  demonstrates  that  deficiency  of  Galk  did  not  
rescue  the  Act5C-­‐‑Gal4>UAS-­‐‑YCanAact  lethality  phenotype.    The  rescue  of  the  CanAact  
phenotype  by  deficiency  of  Galk  was  not  universal  (Figure  23).    However,  these  results  
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do  not  rule  out  the  possibility  that  the  level  of  Galk  disruption  was  not  sufficient  to  
rescue  the  lethality  due  to  the  severity  of  the  phenotype.  
  
  
Figure  23:  Deficiency  of  Galk  rescued  Act5C-­‐‑Gal4>UAS-­‐‑YCanAact-­‐‑induced  
lethality.  
Number  of  progeny  expressing  the  respective  phenotypes  from  the  cross.    No  
progeny  were  produced  expressing  Act5C-­‐‑Gal4>UAS-­‐‑YCanAact,  showing  that  deficiency  
of  Galk  did  not  rescue  Act5C-­‐‑Gal4>UAS-­‐‑YCanAact  -­‐‑induced  lethality.  (Fisher’s  exact  test  
comparing  percentage  of  viable  flies  expressing  Act5C-­‐‑Gal4>UAS-­‐‑YCanAact  with  
deficiency  to  without  deficiency.)  
  
  
5.5.3 Deficiency of Galk did not rescue dpp-Gal4>UAS-YCanAact-
induced wing abnormality  
The  effect  of  driving  UAS-­‐‑YCanAact  ectodermally  with  the  dpp-­‐‑Gal4  driver  was  
evaluated.    Ectodermal  dpp-­‐‑Gal4>UAS-­‐‑YCanAact  caused  an  abnormal  wing  phenotype  
where  the  wing  was  unable  to  expand  (Figure  24).    Progeny  from  the  cross  dpp-­‐‑
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normal  winged  progeny  expressing  dpp-­‐‑Gal4>UAS-­‐‑YCanAact  was  increased  in  the  context  
of  Df(3L)ED4416,  this  would  signify  a  rescue.    Results  showed  that  there  was  no  
significant  increase  in  normal-­‐‑winged  progeny.    These  results  suggest  that  Galk  does  not  
modify  CanAact  in  ectodermal  tissue.    However,  it  is  possible  that  the  level  of  Galk  
disruption  was  not  sufficient  to  rescue  the  phenotype  even  if  Galk  does  play  a  role  
downstream  to  CanAact  in  ectodermal  tissue.  
  
  
Figure  24:  Deficiency  encompassing  Galk  did  not  rescue  dpp-­‐‑Gal4>UAS-­‐‑
YCanAact-­‐‑induced  abnormal  wing  phenotype.  
Images  show  the  wing  of  control  w1118  and  dpp-­‐‑Gal4>UAS-­‐‑YCanAact  flies.    Flies  
expressing  dpp-­‐‑Gal4>UAS-­‐‑YCanAact  show  an  abnormal  wing  phenotype  where  the  wing  
fails  to  expand  after  eclosion.    Bottom  figure  shows  the  percentage  and  number  of  total  
abnormal  winged  progeny  expressing  the  respective  genotypes  from  the  cross  dpp-­‐‑
Gal4/CyO  x  YCanAact/CyO;Df(3L)ED4416/TM2.    Deficiency  encompassing  Galk,  
CanAact-induced wing phenotype
w1118 dpp-Gal4>UAS-YCanAact





0% (N=0/20) 0% (N=0/14)
72.22% (N=8/11) 69.59% (N=16/23)
   (No rescue)
Df(3L)ED4416
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Df(3L)ED4416,  did  not  rescue  wing  abnormality  of  dpp-­‐‑Gal4>UAS-­‐‑YCanAact  flies.  
(Fisher’s  exact  test  comparing  the  percentage  of  abnormal  winged  flies  expressing  dpp-­‐‑




5.5.4 Deficiency of Galk did not rescue Mef2-Gal4>UAS-YCanAact-
induced lethality  
The  above  experiments  showed  that  Galk  modified  UAS-­‐‑YCanAact  phenotypes  in  
a  tissue-­‐‑specific  manner.    I  next  examined  the  effect  of  driving  UAS-­‐‑YCanAact  with  a  
mesodermal  Mef2-­‐‑Gal4  driver.    Driving  CanAact  expression  in  the  mesoderm  with  Mef2-­‐‑
Gal4>UAS-­‐‑YCanAact  led  to  late  pupal  lethality  where  pharate  adults  failed  to  emerge  
from  the  pupa.    This  result  was  consistent  with  the  observations  of  Gajewski  et  al,  who  
reported  that  ectopic  expression  of  CanAact  with  the  24B-­‐‑  driver  also  causes  pupal  
lethality  due  to  defects  of  flight  muscle  development.    If  disruption  of  Galk  rescued  Mef2-­‐‑
Gal4>UAS-­‐‑YCanAact-­‐‑induced  pupal  lethality,  viable  progeny  will  be  recovered  in  the  
context  of  disruption  of  Galk  with  Mi{ET1}GalkMB10638  or  Df{3L}ED4416.    Mi{ET1}GalkMB10638  
or  Df{3L}ED4416  was  put  into  the  context  of  Mef2  by  crossing  Mef2-­‐‑Gal4  flies  with  UAS-­‐‑
YCanAact/CyO;Mi{ET1}GalkMB10638/MKRS  or  UAS-­‐‑YCanAact/CyO;Df{3L}ED4416/MKRS  flies.    
No  viable  progeny  expressing  Mef2-­‐‑Gal4>UAS-­‐‑YCanAact  were  recovered  in  the  context  of  
either  Mi{ET1}GalkMB10638  or  Df{3L}ED4416,  indicating  that  disruption  of  Galk  did  not  
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rescue  the  Mef2-­‐‑Gal4>UAS-­‐‑YCanAact  -­‐‑induced  pupal  lethality  (Figure  25).    Whether  this  




Figure  25:  Disruption  of  Galk  did  not  rescue  Mef2-­‐‑Gal4>UAS-­‐‑YCanAact-­‐‑
induced  pupal  lethality.  
Experiments  were  performed  to  determine  if  disruption  of  Galk  rescues  Mef2-­‐‑
Gal4>UAS-­‐‑YCanAact-­‐‑induced  lethality.    Flies  expressing  Mef2-­‐‑Gal4  were  crossed  to  either  
UAS-­‐‑YCanAact/CyO  flies  with  A)  Df{3L}ED4416  or  B)  Mi{ET1}GalkMB10638  over  the  MKRS  
balancer  on  the  third  chromosome.    The  number  of  resulting  progeny  expressing  the  
corresponding  genotypes  was  counted.    No  progeny  expressing  Mef2-­‐‑Gal4>UAS-­‐‑
YCanAact  were  recovered  from  the  cross,  indicating  that  deficiency  Df{3L}ED4416  
encompassing  Galk  and  disruption  of  Galk  with  Mi{ET1}GalkMB10638  did  not  rescue  the  










0 0 (No rescue)
Recovered progeny from
Mef2-Gal4 x UAS-YCanAact/CyO;Mi{ET1}GalkMB10638/MKRS




0 0 (No rescue)
     89  
of  viable  flies  expressing  Mef2-­‐‑Gal4>UAS-­‐‑YCanAact  with  or  without  deficiency  or  
insertion.)  
  
5.6 Knocking down Galk1 in H9c2 and NIH-3T3 cells did not 
affect calcineurin-induced NFAT translocation 
I  went  on  to  further  explore  the  role  of  Galk  in  calcineurin  signaling  in  
mammalian  cell  lines.    Ionomycin  is  an  ionophore  which  increases  calcium  concentration  
in  the  cell,  thereby  activating  calcineurin  by  calcium/calmodulin  and  CanB  binding.    
NFAT-­‐‑GFP  was  transfected  into  cells  to  examine  NFAT  translocation.    NFAT-­‐‑GFP  
translocation  was  activated  downstream  of  ionomycin-­‐‑induced  calcineurin  activation.    
An  siRNA  to  a  mammalian  homologue  of  Galk,  Galk1,  was  found  to  effectively  knock  
down  Galk1  expression  and  was  used  to  investigate  the  role  of  Galk1  on  calcineurin-­‐‑
induced  NFAT  translocation.    If  Galk1  played  a  role  in  modifying  the  calcineurin/NFAT  
pathway,  NFAT  translocation  would  be  altered  with  siRNA  to  Galk1.    Results  showed  
that  NFAT  translocation  was  not  altered  by  knocking  down  Galk1  in  the  NIH-­‐‑3T3  mouse  
fibroblast  cell  line  or  the  H9c2  rat  cardiomyoblast  cell  line  (Figure  26).  
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Figure  26:  Knocking  down  Galk  with  siRNA  in  NIH-­‐‑3T3  fibroblast  and  H9c2  
cells  did  not  alter  calcineurin-­‐‑activated  NFAT  translocation.  
A)  Transiently  transfected  NFAT-­‐‑GFP  localization  with  or  without  the  
calcineurin  activator  ionomycin  (0.1  µμM)  or  siRNA  to  Galk1.    Ionomycin  induces  NFAT  
translocation  into  the  cell  nucleus  in  NIH-­‐‑3T3  mouse  fibroblasts  and  H9c2  rat  
cardiomyoblasts.    This  translocation  is  not  inhibited  by  knocking  down  Galk1  with  
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translocated  NFAT  between  control  and  siRNA  groups.)    B)  Western  blot  showed  that  
siRNA  to  Galk1  reduced  Galk1  protein  expression  in  both  NIH-­‐‑3T3  and  H9c2  cells.     






Chapter 6. A deficiency region on chromosome 2L 
rescued CanAact-induced cardiac enlargement 
Previous  results  in  this  study  established  a  feasible  method  for  screening  for  
novel  modifiers  of  CanAact-­‐‑induced  cardiac  enlargement.    Utilizing  this  method,  another  
region  on  chromosome  2L  in  the  Drosophila  genome  was  screened  for  rescue  of  CanAact-­‐‑
induced  cardiac  enlargement.    This  was  a  region  based  on  Gajewski  et  al  in  their  screen  
for  modifiers  of  the  24B-­‐‑Gal4-­‐‑driven  lethality  phenotype.    Another  deficiency  region  and  
candidate  gene  was  identified  to  modify  CanAact-­‐‑induced  cardiac  enlargement.  
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6.1 A deficiency region on chromosome 2L rescued tinC-
YCanAact-induced cardiac enlargement. 
Another  deficiency  region  that  was  previously  found  to  rescue  24B-­‐‑Gal4  >CanAact-­‐‑
induced  lethality  was  tested  (Table  1).    A  deficiency  region  encompassing  31  genes  was  
analyzed.    Two  deficiency  lines  from  the  Bloomington  deficiency  kit  were  used:  
Df(2L)ED50001  and  Df(2L)ED5857.    As  the  results  show,  Df(2L)ED5857  rescued  tinC-­‐‑
CanAact-­‐‑induced  cardiac  enlargement  while  Df(2L)ED50001  did  not  (Figure  27).    This  
revealed  another  deficiency  region  on  chromosome  2L  encompassing  21  genes.    As  
described  in  Table  3,  several  genes  in  this  region  appear  to  have  high  expression  in  the  
heart  and  may  be  potential  candidate  genes  for  modifiers  of  calcineurin-­‐‑induced  cardiac  
enlargement.  
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Figure  27:  A  deficiency  region  on  chromosome  2L  rescued  tinC-­‐‑YCanAact-­‐‑
induced  cardiac  enlargement.  
A)  Chromosomal  region  covered  by  the  deficiency  lines  Df(2L)ED50001  and  
Df(2L)ED5878.    (Adapted  from  Gbrowse,  http://flybase.org/cgi-­‐‑bin/gbrowse/dmel)    B)  
End-­‐‑diastolic  dimension  and  fractional  shortenings  from  OCT  m-­‐‑mode  images  of  w1118  
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Df(2L)ED50001.    Df(2L)ED5878  rescued  tinC-­‐‑YCanAact  cardiac  enlargement  while  
Df(2L)ED50001  did  not.    The  deficiency  region  delineated  is  outlined  in  grey  dashed  
lines  in  (A).    C)  End-­‐‑diastolic  dimension  and  fractional  shortenings  of  deficiency  lines  on  
their  own  without  tinC-­‐‑YCanAact.    The  deficiency  lines  alone  did  not  cause  cardiac  
enlargement.    (*P<0.0001,  one-­‐‑way  ANOVA  with  Bonferroni  correction.    All  data  
represent  mean  ±SEM.    All  transgenes  were  heterozygous.)  
  
  
Table  3:  Genes  in  the  suppressor  region  on  chromosome  2L  
Gene   Possible  function   Human  orthologue   Expression  in  adult  
heart  
galectin   Galactoside  
binding  
LGALS9   High  
CG11374   Galactoside  
binding  
None   No  
net   transcription.   None   Low  
Zizimin-­‐‑relatd   Rho  GEF   None   Moderate  
CG11377   Calcium  binding   CRELD2   Moderate  
Nhe1   Sodium/hydrogen  
exchanger  






MAT2A   High  
CG11455   NADH  
dehydrogenase  
None     High  
CG13694   unknown   None     No  
CG4822   transporter   None     High  
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CG31976   unknown   None     No    
CG31974   transferase   None   High    
CG11454   mRNA  binding   None     Moderate  
CG42399   unknown   None   No  
Gene  information  obtained  from  flybase.org;  expression  data  obtained  from  flyatlas.org  
  
6.2 Transposable element insertion in galectin rescued tinC-
YCanAact-induced cardiac enlargement 
Galectin,  a  galactoside-­‐‑binding  lectin,  is  known  to  facilitate  protein-­‐‑protein  
interactions  through  binding  to  galactosides  on  cell  surface  proteins.    Interestingly,  
galectin  stood  out  as  a  candidate  because  one  possible  mechanism  by  which  Galk  may  
exert  its  function  is  by  facilitating  glycosylation  of  glycoproteins  with  galactosides.    I  
analyzed  the  effect  of  transposable  elements  in  galectin.    A  P-­‐‑element  insertion  in  
galectin,  P{wHy}galectinDG25505,  rescued  tinC-­‐‑YCanAact-­‐‑induced  cardiac  enlargement  
(Figure  28).    From  these  results,  it  is  postulated  that  galectin  may  be  a  candidate  
modifier  gene  within  the  second  region  for  CanAact-­‐‑induced  cardiac  enlargement.    
Whether  or  not  additional  genes  are  involved  requires  further  experimentation.  
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Figure  28:  P-­‐‑element  insertion  in  galectin  rescued  tinC-­‐‑YCanAact-­‐‑induced  
cardiac  enlargement.  
A)  End-­‐‑diastolic  dimensions  and  B)  Fractional  shortenings  measured  from  OCT  
m-­‐‑mode  images  of  w1118  control  or  Drosophila  expressing  heterozygous  tinC-­‐‑YCanAact,  a  P-­‐‑
element  insertion  in  galectin  (P{wHy}galectinDG25505),  and  tinC-­‐‑YCanAact  in  the  context  of  
P{wHy}galectinDG25505.    Genetic  disruption  of  galectin  rescued  tinC-­‐‑YCanAact-­‐‑induced  
cardiac  enlargement.    (*P<0.05,  **P<0.0001,  one-­‐‑way  ANOVA  with  Bonferroni  correction.    
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7. Discussion 
Calcineurin  has  been  shown  to  regulate  mammalian  cardiac  hypertrophy;  
understanding  factors  associated  with  calcineurin  signaling  can  lead  to  novel  targets  for  
treating  cardiac  disease.    My  study  utilizes  the  advantages  of  the  Drosophila  melanogaster  
system  to  screen  for  modifiers  of  constitutively  active  calcineurin  (CanAact)-­‐‑induced  
cardiac  enlargement.    I  generated  CanAact-­‐‑expressing  sensitized  Drosophila  lines,  which  
display  cardiac  enlargement  and  screened  for  modifiers  of  CanAact-­‐‑induced  cardiac  
enlargement.    From  this  study,  I  have  1)  demonstrated  that  CanAact  induces  a  significant  
cardiac  phenotype  despite  the  lack  of  calcineurin-­‐‑regulated  NFAT  in  Drosophila,  2)  
established  a  feasible  method  for  discovering  novel  modifiers  of  CanAact  in  the  heart,  3)  
discovered  and  characterized  galactokinase  as  a  novel  modifier  of  CanAact-­‐‑induced  
cardiac  enlargement,  and  4)  discovered  galectin  as  a  potential  modifier  of  CanAact-­‐‑
induced  cardiac  enlargement  from  a  deficiency  region  on  chromosome  2L.  
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7.1 Using Drosophila as a model to discover novel calcineurin 
modifiers in the heart 
My  results  demonstrate  a  significant  cardiac  enlargement  when  overexpressing  
CanAact  in  the  Drosophila  heart.    A  substantial  amount  of  research  has  accumulated  
regarding  calcineurin-­‐‑induced  cardiac  hypertrophy  in  mice  [9,  19,  28,  73,  81,  82,  91,  94,  
215-­‐‑217].    Many  modifiers  of  calcineurin-­‐‑induced  cardiac  hypertrophy  have  been  
discovered,  including  NFAT  [9],  Mef2  [61],  MCIP1  [71],  Cain,  and  AKAP79  [72].    These  
include  factors  that  signal  downstream  of  calcineurin  and  factors  that  regulate  
calcineurin  activity.    These  aspects  of  the  calcineurin  signaling  pathway  are  under  active  
investigation;  however,  it  is  clear  that  additional  regulatory  factors  are  involved.    In  fact,  
a  recent  study  discovered  that  interferon  regulatory  factor  8  (IRF8),  previously  unknown  
to  regulate  calcineurin  signaling,  negatively  regulates  cardiac  hypertrophy  by  inhibiting  
NFAT  [216].    The  fact  that  many  of  these  known  factors  are  absent  from  the  Drosophila  
genome  and  that  powerful  genetic  tools  are  available  for  large  scale  screening  in  the  fly  
indicate  that  Drosophila  provides  a  system  to  investigate  essential  components  
downstream  of  CanAact,  which  may  not  be  discovered  in  a  mammalian  system.    This  is  
evidenced  by  the  discovery  of  two  novel  regulators  of  calcineurin-­‐‑mediated  cardiac  
hypertrophy  in  my  study:  Galk  and  galectin.  
Multiple  signaling  pathways  crosstalk  and  form  a  complex  signaling  pathway  
during  the  onset  of  cardiac  hypertrophy,  with  calcineurin  serving  as  one  branch  of  this  
system.    Many  of  these  pathways  may  have  dual  functionality  and  multiple  pathways  
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may  converge  to  induce  the  phenotype.    For  example,  the  upregulation  of  
calcium/calmodulin  induces  activation  of  PKC,  CaMK,  and  calcineurin  [94,  218];  ERK  
activates  NFAT  while  inhibiting  apoptosis;  Mef2  is  necessary  but  not  sufficient  to  induce  
a  cardiac  hypertrophic  phenotype  [61];  and  MEK1  to  ERK  signaling  is  necessary  but  not  
sufficient  to  induce  concentric  cardiac  hypertrophy  [96].    To  add  to  the  complexity,  
when  comparing  the  genes  upregulated  in  several  different  cardiac  hypertrophy  models,  
the  downstream  activated  genes  did  not  overlap,  indicating  that  the  same  hypertrophic  
phenotype  can  be  elicited  by  the  expression  of  distinct  sets  of  genes  [103].    These  data  
indicate  that  cardiac  hypertrophy  is  a  complex  disease  induced  by  multiple  redundant  
signaling  pathways  that  may  be  differentially  regulated  in  different  patients,  and  
discovering  novel  pathways  has  the  potential  to  benefit  patients  that  are  not  responsive  
to  current  treatments.    In  addition,  more  complete  knowledge  of  the  signaling  pathways  
will  provide  insight  regarding  the  most  beneficial  combination  of  genes  and  proteins  to  
target  for  therapy.  
In  my  study,  I  have  established  the  use  of  Drosophila  as  a  model  enabling  large  
scale  screening  for  novel  genes  that  modify  calcineurin-­‐‑induced  cardiomyopathy.    I  have  
also  identified  two  novel  genes  that  modify  calcineurin-­‐‑induced  cardiac  enlargement.    
Further  exhaustive  deficiency  screening  will  provide  great  insight  into  the  regulation  
and  signaling  of  calcineurin  in  the  heart.  
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7.2 Comparing the CanAact-induced cardiac enlargement 
phenotype in the fly to mammalian cardiac hypertrophy 
Ultimately,  the  goal  is  to  discover  novel  genes  that  also  regulate  mammalian  
cardiac  calcineurin.    Both  the  fly  and  mammalian  models  displayed  significant  
phenotypes  in  the  heart.    However,  the  specific  phenotypes  were  distinct  from  each  
other:  the  α-­‐‑MHC-­‐‑CanAact  mouse  displayed  eccentric  and  concentric  cardiac  hypertrophy  
with  significant  myofibrillar  disarray,  collagen  deposition,  and  premature  death,  while  
the  tinC-­‐‑CanAact  fly  displayed  eccentric  cardiac  hypertrophy,  and  decreased  life  span  
with  no  obvious  myofibrillar  disarray  or  collagen  deposition.  These  descrepancies  may  
be  due  to  the  distinct  cardiac  structures  and  genetic  compositions  of  the  mammalian  and  
fly  hearts.  
  
7.2.1 Eccentric cardiac hypertrophy (increased lumen area) 
The  mouse  model  of  cardiac  CanAact  displayed  several  hypertrophy  phenotypes  
including  eccentric  cardiac  hypertrophy,  which  is  the  dilation  of  the  cardiac  chamber  
due  to  the  addition  of  sarcomeres  in  series  [9].    This  is  the  main  phenotype  that  was  
observed  in  tinC-­‐‑YCanAact  and  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  Drosophila.    Drosophila  do  not  
express  calcineurin-­‐‑mediated  NFAT;  it  can  be  postulated  that  a  mechanism  involving  a  
different  downstream  transcription  factor  may  be  involved,  possibly  Mef2.    
Interestingly,  studies  involving  overexpressing  Mef2  in  mice  show  that  Mef2  
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regulate  this  distinct  aspect  of  the  cardiac  phenotype:  CanAact  mice  still  display  
concentric  hypertrophy  (wall  thickness  increase),  while  eccentric  hypertrophy  (dilation)  
and  cardiac  function  are  rescued  by  expressing  dominant  negative  Mef2.    In  addition,  
overexpressing  Mef2  on  its  own  causes  cardiac  dilation  instead  of  concentric  cardiac  
hypertrophy  [61].    In  my  study,  disrupting  Mef2  rescued  tinC-­‐‑YCanAact  and  tinC-­‐‑
Gal4>UAS-­‐‑YCanAact-­‐‑induced  cardiac  enlargement.    This  suggests  that  calcineurin/Mef2  
may  induce  downstream  signaling  that  leads  towards  eccentric  cardiac  hypertrophy,  
adding  sarcomeres  in  series,  in  the  fly.    In  agreement  with  this,  overexpressing  Mef2  in  
the  Drosophila  heart  induced  cardiac  enlargement  similar  to  the  tinC-­‐‑CanAact  cardiac  
enlargement  phenotype  (Figure  29).    Interestingly,  overexpressing  Mef2  in  the  heart  did  
not  reduce  fractional  shortening,  indicating  that  additional  mechanisms  may  be  
involved  in  controlling  contractility.    The  disruption  of  Galk  with  Mi{ET1}GalkMB10638  
partially  rescued  the  tinC-­‐‑Gal4>UAS-­‐‑Mef2-­‐‑induced  cardiac  enlargement,  suggesting  that  
Galk  modifies  cardiac  enlargement  downstream  of  Mef2.    The  incomplete  rescue  
indicates  that  there  are  additional  pathways  downstream  of  Mef2  that  are  not  regulated  
by  Galk.    In  relation  to  calcineurin,  the  rescue  of  the  tinC-­‐‑CanAact  cardiac  enlargement  
phenotype  by  Mi{ET1}GalkMB10638  (98%  EDD  rescue,  Figure  15)  was  much  greater  than  
that  of  tinC-­‐‑Gal4>UAS-­‐‑Mef2  (48%  EDD  rescue,  Figure  29),  suggesting  that  Galk  also  
regulates  pathways  downstream  of  CanAact  independent  from  Mef2.  
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Figure  29:  Overexpressing  Mef2  in  the  heart  causes  cardiac  enlargement  which  
is  partially  rescued  by  Minos  insertion  in  Galk.  
Quantification  of  the  m-­‐‑mode  OCT  images  of  end-­‐‑diastolic  dimensions  and  
fractional  shortenings  for  heterozygous  tinC-­‐‑Gal4  (driver  only),  UAS-­‐‑Mef2  (no  driver),  
tinC-­‐‑Gal4>UAS-­‐‑Mef2,  and  tinC-­‐‑Gal4>UAS-­‐‑Mef2  in  the  context  of  Mi{ET1}GalkMB10638  
(Mi{ET1}Galk)  fly  hearts.    The  results  show  that  overexpressing  Mef2  in  the  heart  with  
tinC-­‐‑Gal4>UAS-­‐‑Mef2  induces  cardiac  enlargement  and  did  not  decrease  contractility.    
Mi{ET1}GalkMB10638  partially  rescued  tinC-­‐‑Gal4>UAS-­‐‑Mef2-­‐‑induced  cardiac  enlargement.    
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7.2.2 Concentric cardiac hypertrophy (increased wall thickness) 
The  mouse  model  of  cardiac  CanAact  displayed  severe  concentric  cardiac  
hypertrophy  where  the  ventricular  wall  was  2-­‐‑3  times  thicker  than  in  control  mice  [9].    
The  tinC-­‐‑YCanAact  fly  did  not  replicate  this  wall  thickness  phenotype;  however,  
compared  to  control,  the  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  fly  did  display  a  2-­‐‑fold  increase  in  
wall  thickness.    The  discrepancy  between  the  tinC-­‐‑YCanAact  and  tinC-­‐‑Gal4>UAS-­‐‑YCanAact  
fly  models  is  most  likely  due  to  increased  expression  level  using  the  Gal4/UAS  bipartite  
system.    Concentric  cardiac  hypertrophy  results  from  the  induction  of  signaling  cascades  
leading  to  the  addition  of  sarcomeres  in  parallel  [219].    I  postulate  that  this  higher  level  
of  expression  induced  sarcomere  formation  in  parallel  as  a  result  of  excessive  signaling.    
However,  studies  specifically  examining  the  number  of  sarcomeres  making  up  the  
cardiac  wall  are  required  to  confirm  this  notion.    
  
7.2.3 Cardiac contractility 
Decreased  contractility  was  observed  in  CanAact  transgenic  mouse  hearts  as  was  
observed  in  tinC-­‐‑CanAact  fly  hearts  [215].    However,  overexpressing  Mef2  in  the  fly  heart  
with  tinC-­‐‑Gal4>UAS-­‐‑Mef2  did  not  induce  a  decrease  in  cardiac  contractility  (fractional  
shortening,  Figure  29).    This  data  suggests  that  the  cardiac  enlargement  phenotype  can  
be  separated  from  the  contractility  phenotype  and  may  be  regulated  through  distinct  
factors.    Previous  examples  support  this  case:  the  ablation  of  phospholamban  and  
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overexpression  of  S100A1  increase  contractility  without  affecting  hypertrophy,  while  
S100A1  null  mice  display  decreased  contractile  function  after  pressure-­‐‑overload  with  no  
effect  on  hypertrophy  [220-­‐‑222].    However,  this  result  also  shows  that  the  fly  
contractility  phenotype  cannot  be  completely  correlated  with  the  mouse  contractility  
phenotype  since  overexpressing  Mef2  in  the  mouse  heart  does  decrease  cardiac  
contractility  [217].    
  
7.2.4 Heart failure 
Heart  failure  is  defined  as  the  condition  where  cardiac  function  is  insufficient  to  
sustain  normal  bodily  functions.    This  is  not  easily  monitored  in  the  fly.    In  an  RNAi  
screen  in  Drosophila  heart  to  identify  genes  relevant  to  cardiac  disease,  Penninger  et  al.  
discovered  that  knock-­‐‑down  of  Not3  results  in  increased  end-­‐‑systolic  dimension  and  
decreased  fractional  shortening.    In  this  study,  Not3+/-­‐‑  mice  displayed  heart  failure  with  
arrhythmia  and  sudden  death,  suggesting  an  example  where  decreased  fractional  
shortening  in  flies  can  correlate  to  mammalian  heart  failure  [182].    In  addition,  Wessells  
and  Bodmer  utilized  screening  of  arrhythmia  or  arrest  with  response  to  electrical  pacing  
stress  as  an  indication  of  heart  failure  [199].    Even  though  my  study  did  not  directly  
address  heart  failure,  tinC-­‐‑CanAact  flies  display  significantly  shorter  life  spans,  implying  
that  the  cardiac  function  of  tinC-­‐‑CanAact  flies  was  insufficient  to  maintain  a  normal  life  
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span.    This  is  also  similar  to  the  findings  by  Molkentin  et  al,  where  cardiac  CanAact  
expressing  mice  experienced  sudden  premature  death  [9].  
  
7.2.5 Myofibrillar disarray and fibrosis 
In  addition  to  the  above-­‐‑mentioned  phenotypes,  the  mouse  model  of  cardiac  
CanAact  displayed  myofibrillar  disarray  and  fibrosis.    Although  not  rigorously  tested,  
these  phenotypes  were  not  observed  in  the  fly  model.    This  may  be  due  to  the  difference  
in  cardiac  structure  between  flies  and  mammals.      
The  mammalian  heart  is  constituted  by  multiple  layers  of  cardiomyocytes  that  
are  elongated,  branching  fibers,  organized  in  tandem  to  facilitate  contraction  while  
Drosophila  hearts  are  one  cell  layer  thick,  organized  in  a  tube  structure  with  one  cell  on  
each  side,  two  opposing  cells  interconnecting  to  form  a  tube.    It  is  plausible  that  the  
simplified  structure  of  the  Drosophila  cardiac  tube  allows  for  more  uniform  enlargement  
with  the  addition  of  sarcomeres  that  does  not  cause  disarray  due  to  lack  of  multiple  cell  
layers.    As  for  fibrosis,  fibroblast  cells  are  present  in  mammalian  hearts  to  produce  
extracellular  matrix  and  facilitate  wound  healing;  however,  they  are  not  present  in  the  
fly  heart.    Thus,  it  is  conceivable  that  fibrosis  is  not  evident  in  Drosophila  hearts.  
  
     107  
7.3 Disruption of Doc and Argk did not rescue CanAact-induced 
cardiac enlargement. 
Several  potential  genes  were  ruled  out  as  modifiers  from  our  original  candidate  
region.    The  Doc  genes  are  known  to  regulate  Drosophila  cardiac  development  [213].    Our  
study  showed  that  RNAi  against  Doc2  and  Doc3  caused  cardiac  enlargement  and  did  not  
rescue  tinC-­‐‑CanAact.    This  implies  that  Doc  genes  are  important  for  cardiac  development  
but  are  not  regulated  by  calcineurin  activation.    Interestingly,  deficiencies  encompassing  
all  three  Doc  genes  did  not  cause  cardiac  enlargement.    This  may  be  due  to  the  different  
Doc  genes  playing  different  roles  during  cardiac  development.    Decreasing  expression  to  
less  than  half  of  the  normal  amount  induced  a  phenotype,  while  decreasing  all  three,  
each  at  50%  the  normal  amount,  did  not  cause  a  phenotype.    Alternatively,  there  may  be  
a  nearby  modifier  gene  that  inhibits  the  cardiac  enlargement  caused  by  Doc  deficiency.  
Argk  has  high  expression  in  the  adult  Drosophila  heart.    Argk  is  an  enzyme  that  
transfers  the  phosphate  on  ATP  to  arginine,  creating  an  energy  rich  buffer  for  
maintaining  ATP  concentration  [223].    Even  though  Argk  does  not  have  close  
mammalian  orthologs,  the  function  is  analogous  to  that  of  mammalian  creatine  kinase.    
While  it  is  conceivable  that  Argk  functions  to  provide  sufficient  energy  for  the  fly  
myocardium,  our  results  showed  that  disrupting  Argk  with  a  transposable  element  did  
not  produce  a  phenotype  and  did  not  rescue  calcineurin-­‐‑induced  cardiac  enlargement.    
These  results  suggest  that  Argk  does  not  regulate  calcineurin-­‐‑induced  cardiac  
enlargement.    Although  a  caveat  to  this  conclusion  is  that  the  transposable  element  
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insertion  PBac{PB}ArgKf05255  displayed  only  a  30%  decrease  in  expression,  and  this  may  
have  interfered  with  the  ability  to  rescue  the  cardiac  enlargement  phenotype.  
  
7.4 Genetic disruption of Galk rescued UAS-CanAact-induced 
phenotypes tissue specifically 
The  screen  I  performed  was  based  on  two  previous  screens  for  calcineurin  
modifiers  performed  using  two  different  tissues,  including  one  expressing  CanAact  in  the  
eye  and  one  expressing  CanAact  mesodermally  with  a  24B  driver.    A  total  of  70,000  X-­‐‑ray  
or  EMS  mutagenized  flies  were  examined  for  both  enhancers  and  suppressors  of  the  
GMR-­‐‑Gal4>UAS-­‐‑CanAact-­‐‑induced  rough  eye  phenotype  [10];  in  the  other  study,  
deficiency  kits  spanning  chromosomes  2  and  3  maximally  were  screened  for  suppressors  
of  the  24B-­‐‑Gal4>UAS-­‐‑CanAact-­‐‑induced  lethality  phenotype  [11].    Interestingly,  the  
modifier  regions  rarely  overlapped  between  these  two  studies:  both  studies  found  canB2  
as  a  modifier  and  66F5  on  chromosome  3L  to  span  potential  modifiers  (Table  1).    The  eye  
phenotype  mutagenesis  screen  discovered  a  suppressor  and  enhancer  region  that  was  
much  larger  in  span,  and  I  initiated  my  screen  with  a  broader  region  than  initially  
discovered  by  Gajewski  et  al.    Galk  does  not  lie  within  but  adjacent  to  the  Gajewski  et  al.  
suppressor  region.    My  data  also  indicated  that  Mef2-­‐‑Gal4>UAS-­‐‑CanAact  lethality  was  not  
rescued  by  Galk  disruption.    Taken  together,  it  may  be  suggested  that  Galk  does  not  
modify  mesodermally  driven  lethality  phenotypes.    I  had  attempted  over-­‐‑expressing  
GMR-­‐‑Gal4>UAS-­‐‑CanAact  in  the  eye  to  see  if  Galk  may  be  a  candidate  modifier  gene  for  
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the  region  described  by  Sullivan  and  Rubin.    However,  difficulties  were  encountered  
due  to  a  subtle  rough  eye  phenotype  in  the  driver  alone  flies  and  variation  in  the  eye  
phenotype  with  CanAact.    Further  experiments  with  a  more  robust  driver  line  may  
facilitate  in  determining  whether  Galk  corresponds  to  a  modifier  in  the  eye  screen  
performed  by  Sullivan  and  Rubin.  
In  my  study,  genetic  disruption  of  Galk  rescued  the  CanAact  phenotypes  induced  
by  tinC-­‐‑Gal4  in  the  heart  and  e16E-­‐‑Gal4  in  the  posterior  wing  imaginal  disc,  but  the  
phenotypes  induced  by  expression  with  several  other  drivers  were  not  rescued.    These  
included  ubiquitous  Act5C-­‐‑Gal4,  ectodermal  dpp-­‐‑Gal4,  and  mesodermal  Mef2-­‐‑Gal4  
drivers.    Table  4  summarizes  the  expression  pattern  of  the  different  drivers  investigated.    
Each  of  these  drivers  induces  expression  in  a  separate  set  of  tissues.    Even  though  both  
e16E-­‐‑  and  dpp-­‐‑driving  CanAact  induced  wing  phenotypes,  e16E-­‐‑  drives  expression  in  the  
posterior  wing,  while  dpp-­‐‑  drives  expression  anterior  to  the  anterior-­‐‑posterior  boundary  
during  imaginal  disc  development  at  the  third  instar  larva  stage  [224,  225].    Many  
signaling  factors  are  differentially  expressed  during  wing  development  in  these  two  
separate  compartments  to  guide  correct  patterning.    For  example,  engrailed  and  hedgehog  
are  expressed  posteriorly,  guiding  formation  of  the  posterior  wing  veins  [224,  226],  
while  dpp  and  the  EGFR  inhibitor  knot  are  expressed  specifically  in  the  anterior  wing  
imaginal  disc  [225,  227].    It  is  possible  that  Galk  modification  of  calcineurin  signaling  is  
regulated  by  these  differentially  expressed  factors.  
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In  addition,  dpp-­‐‑Gal4,  Mef2-­‐‑Gal4,  and  Act5C-­‐‑Gal4  all  induce  expression  in  a  broad  
band  of  cells,  which  further  differentiate  to  form  a  wide  range  of  tissues.    It  is  possible  
that  these  three  genes  are  expressed  in  an  overlapping  region  that  causes  the  
corresponding  CanAact  phenotype,  and  Galk  does  not  regulate  CanAact  in  that  tissue.    
However,  this  is  less  plausible  by  analyzing  expression  patterns  in  Table  4,  dpp-­‐‑Gal4  and  
Mef2-­‐‑Gal4  do  not  seem  to  have  overlapping  expression.    It  is  more  likely  that  Galk  
disruption  did  not  rescue  the  CanAact  phenotypes  because  of  the  lack  of  Galk  
modulation  in  separate  tissues  corresponding  to  each  driver.    For  example,  it  appears  
that  the  dpp-­‐‑Gal4>UAS-­‐‑YCanAact  fly  displays  a  fully  developed  wing  that  fails  to  expand  
upon  eclosion.    The  expansion  of  the  Drosophila  wing  after  eclosion  is  an  integrated  
process  that  involves  programed  cell  death  in  the  wing,  following  the  induction  of  a  
neuroendocrine  cascade  and  epithelial-­‐‑mesenchymal  transition  after  eclosion  [228,  229].    
It  is  plausible  that  CanAact  disrupts  one  of  these  processes,  and  this  is  not  regulated  by  
Galk.    The  dpp-­‐‑Gal4,  Mef2-­‐‑Gal4,  and  Act5C-­‐‑Gal4  driven  phenotypes  are  also  more  severe  
all-­‐‑or-­‐‑none  phenotypes  compared  to  tinC-­‐‑  and  e16E-­‐‑Gal4  phenotypes  that  display  a  
range  of  abnormalities  where  a  lower  level  of  disruption  will  result  in  a  quantifiable  
rescue.    It  is  possible  that  the  level  of  Galk  disruption  was  not  sufficient  to  rescue  these  
more  severe  phenotypes  even  if  Galk  was  acting  in  these  tissues.  
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Table  4:  Expression  pattern  of  Gal4  lines  driving  expression  of  UAS-­‐‑YCanAact  
in  the  current  study  
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7.5 Galactokinase in mammals 
My  study  has  concluded  that  galactokinase  may  be  involved  in  calcineurin-­‐‑
induced  cardiomyopathy.    There  is  limited  literature  regarding  the  relevance  of  Galk  to  
calcineurin  signaling  or  cardiomyopathy.    Two  Galk  homologs  are  expressed  in  
mammals,  Galk1  and  Galk2.    The  major  defect  of  humans  and  mice  deficient  for  Galk1  is  
cataracts  and  mental  and/or  motor  neurological  disorders  [236,  237].    Cardiac  defects  
have  not  been  specifically  observed  in  these  studies  and  no  known  mutations  in  Galk2  
have  been  studied.    In  addition,  my  data  showed  that  Galk  itself  may  not  affect  cardiac  
function  on  its  own  without  calcineurin.    Further  studies  are  pending  to  investigate  
whether  or  not  Galk  modifies  calcineurin  in  the  mammalian  heart.  
Also  affecting  glycosylation,  a  phosphoglucomutase  1  (PGM1)  mutation  was  
found  in  humans  to  cause  cardiac  abnormalities  including  dilated  cardiomyopathy  and  
cardiac  arrest  [238].    In  this  study,  supplementing  fibroblast  cells  with  galactose  
alleviated  glycosylation  defects  from  PGM1  mutation.    This  study  demonstrates  that  
galactoside  modifications  are  important  for  cardiac  function.    Another  study  found  that  
overexpressing  the  Galβ1,3GalNAc  α2,3-­‐‑sialyltransferase  II  (ST3Gal-­‐‑II),  inducing  
abnormal  protein  glycosylation,  induced  dilated  cardiomyopathy  in  transgenic  mice  
[239].    These  studies  corroborate  that  Galk  and  glycosylation  are  important  for  normal  
cardiac  function.  
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7.6 Galactokinase as a novel modifier of calcineurin: possible 
mechanisms 
Galactokinase  belongs  to  the  GHMP  ATP-­‐‑dependent  kinase  family  (named  after  
the  four  representative  kinases  in  this  family:  galactokinase,  homoserine  kinase,  
mevalonate  kinase,  and  phosphomevalonate  kinase)  [214].    In  the  fly,  galactokinase  
phosphorylates  galactose  and  N-­‐‑acetyl-­‐‑galactosamine,  allowing  further  utilization  in  
either  metabolism  (energy  production)  or  glycosylation  (protein  modification)  [214].    
These  pathways  potentially  lead  to  cardiac  enlargement:  either  galactokinase  promotes  a  
higher  level  of  phosphorylated  galactose,  galactose-­‐‑1-­‐‑p,  leading  to  a  diseased  state,  or  
downstream  reactions  involving  UDP-­‐‑galactose  incorporation  into  glycosylated  proteins  
promotes  cardiac  enlargement,  or  both  mechanisms  may  be  required.    These  possible  
pathways  are  summarized  in  Figure  30.    A  previous  screen  examining  Drosophila  cardiac  
development  discovered  that  mutations  in  HMG-­‐‑CoA  reductase  (the  rate-­‐‑limiting  
enzyme  in  the  mevalonate  pathway)  induces  a  cardiac  phenotype  by  
geranylgeranylation  of  the  G  protein  Gγ1,  suggesting  a  pathway  by  which  post-­‐‑
translational  modifications  can  alter  the  fly  heart  [240].  
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Figure  30:  Galactokinase-­‐‑related  pathways  
Galactokinase  (Galk),  in  the  red  box,  catalyzes  the  phosphorylation  of  β-­‐‑D-­‐‑
Galactose/GalNAc  into  Galactose/GalNAc-­‐‑1-­‐‑Phosphate.    This  potentially  influences  
metabolism  by  conversion  into  UDP-­‐‑Glucose  and  utilization  for  ATP  production,  or  
conversion  into  UDP-­‐‑Galactose/GalNAc,  facilitating  glycosylation  through  respective  
glycosyltransferases.    (Abbreviations:  GalNAc=  N-­‐‑Acetyl-­‐‑Galactosamine;  Galm=  
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        In  addition  to  the  well  known  affects  of  galactokinase  related  to  galactose/GalNAc  
metabolism,  the  yeast  homologue  of  Galk,  Gal3p,  has  been  found  to  act  as  a  
transcriptional  activator  by  interacting  with  Gal80p  [241];  transcriptional  regulation  is  
activated  with  the  binding  of  galactose  and  ATP  to  Gal3p.    This  suggests  the  possibility  
that  Galk  may  act  as  a  modifier  of  transcription  for  known  pathways  including  Mef2.    
Whether  Galk  functions  as  part  of  the  transcriptional  machinery  remains  to  be  
determined.    Co-­‐‑immunoprecipitation  experiments  for  Galk-­‐‑  Mef2  interaction  and  
luciferase  assay  for  Mef2-­‐‑luciferase  reporter  gene  activation  with  RNAi  to  Galk  in  the  
context  of  CanAact  can  be  performed  to  determine  this.  
  
  
7.7 Galectin is a possible downstream regulator of Galk in 
CanAact-induced cardiac enlargement. 
The  function  of  Galk  is  to  phosphorylate  Galactose/N-­‐‑Acetyl-­‐‑Galactosamine  
(GalNAc)  to  form  Galactose/GalNAc-­‐‑1-­‐‑P.    Both  Galactose  and  GalNAc  are  commonly  
found  in  glycoproteins  and  is  important  for  normal  function.    My  study  shows  that  a  
transposable  element  insertion  in  galectin  (a  galactoside-­‐‑binding  lectin)  suppressed  the  
tinC-­‐‑CanAact  cardiac  phenotype.    Mammalian  Galectin3  has  been  shown  to  bind  to  the  N-­‐‑
acetyllactosamine  on  EGFR,  preventing  endocytosis  and  enhancing  signaling  of  isolated  
mouse  mammary  cells  [242].    Driving  activated  EGFR  in  the  Drosophila  heart  has  been  
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shown  to  induce  a  cardiac  hypertrophy  phenotype  while  dominant  negative  EGFR  
induces  a  dilation  phenotype  [194]  and  sprouty,  a  negative  regulator  of  EGFR  signaling,  
has  been  shown  to  modify  calcineurin-­‐‑induced  rough  eye  [10].    Although  speculation,  
one  potential  mechanism  by  which  galactokinase  functions  to  modulate  calcineurin-­‐‑
induced  cardiac  enlargement  is  by  influencing  co-­‐‑translational  glycosylation  of  EGFR  or  
another  yet  unidentified  cell  surface  protein  that  is  bound  by  galectin.  
Based  on  these  findings  and  previously  published  literature,  I  propose  a  possible  
mechanism  for  Galk  modification  of  calcineurin-­‐‑induced  cardiac  enlargement  (Figure  
31).    I  propose  that  calcineurin  indirectly  activates  Galk,  regulating  glycosylation  of  a  cell  
surface  receptor  (possibly  EGFR),  which  is  bound  by  galectin.    Galectin  facilitates  
dimerization  and  activation  of  downstream  signaling  factors  which  regulate  either  
unknown  transcription  factors  or  Mef2  activation,  leading  to  cardiac  enlargement.    
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Figure  31:  Possible  mechanism  for  Galk  regulation  of  calcineurin-­‐‑induced  
hypertrophy.  
Galactokinase  and  galectin  may  cooperate  in  modifying  calcineurin  downstream  
activation  of  hypertrophy.    Pathways  with  possibly  indirect  effects  are  shown  with  
dashed  lines.    CnB=  Calcineurin  B;  p=  phosphate.    While  speculative,  a  possible  
mechanism  that  links  Galk  and  galectin  is  by  their  action  on  galactose/GalNAc.    
Galactokinase  regulates  the  phosphorylation  of  galactose/GalNAc,  allowing  for  
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galactose/GalNAc  is  then  transferred  on  to  cell  surface  receptor  proteins  that  are  
recognized  and  bound  by  galectin,  possibly  altering  signal  transduction  downstream  of  
the  receptor  proteins  to  modify  downstream  cardiac  enlargement.  
  
  
7.8 Therapeutic possibilities 
Cardiac  hypertrophy  is  a  complex  disease  involving  multiple  signaling  
pathways.    Previous  studies  have  not  examined  the  effects  of  Galk  in  the  mammalian  
heart.    My  studies  show  that  Galk  is  a  modifier  downstream  of  calcineurin.    This  implies  
that  pharmacological  inhibition  of  Galk  may  be  beneficial  to  treating  cardiac  
hypertrophy.    Even  though  Galk  inhibitors  are  not  commonly  administered,  previous  
studies  have  tested  multiple  small  molecular  compounds  that  specifically  inhibit  Galk1  
[243].    Out  of  50,000  compounds,  150  compounds  were  found  to  inhibit  Galk1,  and  34  of  
these  were  further  characterized.    Less  research  has  been  conducted  examining  Galk2.    
However,  since  Galk1  and  Galk2  share  similar  domain  structures,  it  is  plausible  that  a  
portion  of  these  inhibitors  may  inhibit  Galk2.    In  addition,  the  Galk1  inhibitors  
discovered  had  common  characteristics  including  multiple  carbon  ring  structures,  at  
least  one  aromatic  ring  structure,  and  at  least  2  hydrogen-­‐‑bond  acceptor  sites.    
Examining  similar  small  molecular  structures  may  reveal  compounds  specific  to  Galk2  
as  well.    
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7.9 Conclusions and impact 
In  conclusion,  I  have  1)  characterized  CanAact-­‐‑induced  cardiomyopathy  in  the  fly;  
2)  established  a  reliable  model  for  discovering  novel  modifiers  of  calcineurin-­‐‑mediated  
cardiac  enlargement  and  through  this  screen;  3)  identified  galactokinase  as  a  modifier  of  
constitutively  active  calcineurin-­‐‑induced  cardiomyopathy,  shortened  life  span,  and  wing  
vein  abnormality  in  adult  Drosophila;  and  4)  identified  galectin  as  a  potential  modifier  of  
constitutively  active  calcineurin-­‐‑induced  cardiomyopathy.    My  study  has  provided  a  
basis  for  performing  unbiased  and  exhaustive  studies  for  understanding  calcineurin  
signaling  in  the  Drosophila  heart  and  novel  insight  into  downstream  regulation  of  
calcineurin-­‐‑induced  cardiomyopathy.    Identification  of  galactokinase  and  galectin  as  
modifiers  of  calcineurin-­‐‑induced  cardiomyopathy  bring  light  to  the  importance  of  
galactose  metabolism  and  glycosylation  in  cardiomyopathy.    These  findings  have  the  
potential  to  further  our  understanding  of  cardiac  hypertrophy  and  heart  failure  by  
revealing  novel  pathways  that  may  be  targeted  in  combination  with  other  treatments  for  
more  effective  therapy.  
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7.10 Future directions 
This  study  provides  the  basis  for  future  research,  including  more  rigorous  
characterization  of  the  calcineurin  fly,  further  screening  for  novel  modifiers  of  
calcineurin  signaling,  and  characterization  of  the  role  of  Galk  in  calcineurin  signaling.  
7.10.1 Characterization of the cardiac CanAact-induced phenotypes 
I  have  established  that  the  tinC-­‐‑CanAact  fly  displays  significant  cardiac  
enlargement.    This  enlargement  is  due  to  hypertrophy  of  individual  cells  and  not  to  
proliferation.    It  was  preliminarily  noted  by  confocal  imaging  that  no  significant  
alterations  in  fiber  structure  is  visible.    However,  this  has  not  been  rigorously  tested.    
Further  studies  using  electron  microscopy  (EM)  will  provide  more  detailed  information  
regarding  the  sarcomeric  structure  of  tinC-­‐‑CanAact  versus  wildtype  flies.    Phalloidin  
staining  followed  by  fluorescence  microscopy  will  also  be  potentially  useful  in  
determining  the  fiber  structure.    In  addition,  examining  the  mitochondria  of  tinC-­‐‑CanAact  
flies  by  EM  will  be  helpful  in  further  determining  the  phenotype  of  the  calcineurin  fly  
and  the  comparison  to  mammalian  cardiomyopathy  phenotypes.    The  mammalian  heart  
displays  a  decrease  in  mitochondria  with  pressure-­‐‑overload  cardiac  hypertrophy  [244-­‐‑
246].  
My  study  showed  that  the  tinC-­‐‑CanAact  fly  displays  a  decrease  in  life  span.    It  is  
postulated  that  this  decrease  in  life  span  is  due  to  an  inability  of  the  heart  to  pump  
normally,  reducing  the  amount  of  oxygen  and  nutrients  provided  to  essential  organs.    
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However,  the  relation  between  cardiac  enlargement  of  tinC-­‐‑CanAact  flies  and  decreased  
hemolymph  flow  was  not  rigorously  tested.    This  has  been  achieved  through  Doppler  
OCT  with  injection  of  a  contrast  agent  (830nm  red  polysterene  beads)  to  visualize  
hemolymph  [247].  
7.10.2 Identification of novel modifiers of calcineurin-induced 
cardiomyopathy  
I  have  established  a  reliable  model  for  detecting  modifiers  of  CanAact-­‐‑induced  
cardiac  enlargement  in  Drosophila.    An  exhaustive  screen  can  be  performed  using  the  
Bloomington  deficiency  kit  which  consists  of  462  fly  stocks  that  maximally  cover  the  fly  
genome  [212,  248].    This  will  potentially  identify  all  of  the  key  molecules  involved  in  
regulation  of  CanAact-­‐‑induced  cardiomyopathy.    Of  note,  this  will  bring  out  many  key  
molecules,  but  we  should  keep  in  mind  that  deficiency  screening  will  not  detect  genes  
that  only  exert  effects  when  the  transcript  level  is  decreased  to  less  than  half  the  normal  
amount,  and  larger  deficiency  regions  potentially  contain  multiple  modifiers  that  may  
interfere  with  the  outcome.    Many  resources  are  available  and  continuously  being  
developed  and  refined  for  targeting  specific  genes  in  Drosophila.    For  knocking  down  or  
disrupting  gene  expression,  transposable  element  insertions,  RNAi,  and  more  recent  
techniques  with  CRISPR/Cas9  and  TALENs  systems  are  available  [163-­‐‑168].    These  
resources  will  prove  useful  in  determining  candidate  molecules  to  fill  in  gaps  in  the  
pathways  discovered  and  generate  a  complete  calcineurin  signaling  network.  
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Within  the  current  suppressor  region,  Argk  cannot  be  completely  ruled  out  as  a  
modifier  due  to  the  incomplete  reduction  of  transcript  by  PBac{PB}Argkf05255.    Many  
systems  are  available  to  generate  knock-­‐‑down  or  knock-­‐‑out  of  gene  expression  including  
RNAi,  CRISPR,  and  TALEN  systems.    The  emerging  CRISPR  system  has  been  utilized  in  
several  studies  and  reported  to  have  less  off-­‐‑target  effects  than  RNAi  [163-­‐‑165].    The  
TALEN  system  is  more  specific  but  requires  more  specialized  techniques  [166-­‐‑168].    The  
logical  next  step  would  be  to  generate  genetic  null  mutations  with  the  CRISPR  system  to  
effectively  target  Argk.      
  
7.10.3 Delineation of the role of Galk in calcineurin-induced 
cardiomyopathy and signaling  
I  have  found  that  Galk  modifies  CanAact-­‐‑induced  cardiomyopathy.    The  
mechanism  by  which  Galk  may  modify  signaling  has  not  been  investigated.    It  is  not  
known  whether  Galk  interacts  with  known  pathways  downstream  of  calcineurin,  or  if  it  
is  an  independent  factor.    Several  approaches  may  be  employed  to  clarify  the  role  of  
Galk  in  calcineurin  signaling.  
The  most  well  documented  role  for  Galk  is  its  role  in  phosphorylating  
galactose/GalNAc,  enabling  utilization  for  glycolysis  or  glycosylation.    Several  
downstream  molecules  are  involved  in  either  pathway  (Figure  30).    For  example,  
conversion  into  glucose-­‐‑1-­‐‑phosphate  and  UDP-­‐‑galactose/GalNAc  is  mediated  by  
galactose-­‐‑1-­‐‑phosphate  uridyltransferase  (Galt)  [249].    Glucose-­‐‑1-­‐‑phosphate  is  then  
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converted  into  glucose-­‐‑6-­‐‑phosphate  with  phosphoglucomutase  [250],  which  is  utilized  in  
glycolysis  to  generate  ATP  [251].    On  the  glycosylation  side,  UDP-­‐‑glucose-­‐‑transferase  
and  UDP-­‐‑galactose/GalNAc  glycosyltransferases  regulate  glycosylation  downstream  of  
galactokinase  [252].    Overexpressing  these  downstream  enzymes  controlling  either  
glycolysis  or  glycosylation  in  the  context  of  tinC-­‐‑CanAact  and  Mi{ET1}GalkMB10638  will  
provide  insight  into  which  of  these  pathways  is  primarily  influencing  the  phenotype.  
It  is  not  known  whether  Galk  interacts  with  known  pathways  downstream  of  
calcineurin  signaling.    Currently,  Mef2  is  the  most  direct  and  well  characterized  modifier  
of  calcineurin  signaling.    Examining  the  effects  of  Galk  overexpression  in  the  context  of  
Mef2  deficiency,  or  Mef2  overexpression  with  Galk  deficiency  in  tinC-­‐‑CanAact  flies  will  
provide  insight  into  whether  these  molecules  interact.    Another  possible  function  of  
Galk  is  in  the  transcriptional  machinery.    Determining  whether  Galk  binds  to  Mef2  via  
immunoprecipitation  and  if  transcription  activation  is  altered  in  Galk  deficient  flies  
using  a  Mef2-­‐‑luciferase  or  IL-­‐‑2  reporter  construct  will  provide  further  insight  into  the  
role  of  Galk  in  the  induction  of  transcription.  
  
7.10.4 Confirmation and characterization of galectin as a modifier of 
calcineurin-induced cardiomyopathy  
Galectin  was  discovered  to  modify  tinC-­‐‑CanAact-­‐‑induced  cardiac  enlargement.    
However,  these  results  should  be  further  confirmed  with  RNAi  knock-­‐‑down  to  ensure  
specificity  of  the  results.    Also,  interaction  of  galectin  with  Galk  by  over-­‐‑expressing  
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galectin  in  Galk  disrupted  flies  in  the  context  of  tinC-­‐‑CanAact  will  provide  insight  as  to  
whether  Galk  and  galectin  are  part  of  the  same  pathway  for  inducing  cardiomyopathy  
downstream  of  calcineurin.    Overexpressing  galectin  will  provide  insight  as  to  whether  
galectin  is  sufficient  to  induce  cardiac  enlargement.  
Further  studies  can  be  performed  to  determine  the  mechanism  by  which  galectin  
influences  calcineurin-­‐‑induced  cardiomyopathy.    Candidate  receptor  genes  including  
EGFR  and  FGFR  can  be  targeted  and  analyzed  in  the  context  of  galectin  deficient  or  
overexpressing  flies  to  assess  for  interaction  between  the  pathways.    In  addition,  
whether  or  not  calcineurin  stimulation  induces  galectin-­‐‑mediated  changes  in  receptor  
recycling  can  be  analyzed  in  cell  culture  using  H9c2  or  NIH-­‐‑3T3  cells.    If  calcineurin  
induces  alterations  in  receptor  expression  or  recycling,  siRNA  to  galectin  can  be  utilized  
to  determine  if  this  process  is  regulated  by  galectin.  
  
7.10.5 Examining the importance of galactose regulation for 
calcineurin-induced cardiac hypertrophy in mammalian systems   
Preliminary  results  indicate  that  Galk1  is  not  involved  in  calcineurin-­‐‑induced  
NFAT  translocation.    However,  whether  Galk1  knock-­‐‑down  affects  calcineurin-­‐‑induced  
Mef2  transcription  activation  remains  to  be  elucidated.    This  can  be  accomplished  using  
Mef2-­‐‑luciferase  reporter  constructs  in  cellular  systems.    I  have  demonstrated  efficient  
Galk1  knock-­‐‑down  and  calcineurin  activation  using  H9c2  and  NIH-­‐‑3T3  cells.    These  cell  
systems  can  be  further  utilized  to  perform  luciferase  assays  to  determine  if  Galk1  
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regulates  Mef2  promoter  activation.    In  addition,  an  appropriate  system  for  Galk2  
remains  to  be  discovered.    Galk2  is  expressed  highly  in  liver  and  heart  tissue.    HL-­‐‑1  cells  
derived  from  primary  cultured  cardiomyocytes  of  mice  expressing  ANF  driving  SV40  
large  T  antigen  is  a  potential  candidate  for  future  investigation  since  primary  cultured  
cardiomyocytes  are  difficult  to  culture  and  manipulate  [253].    Rat  neonatal  
cardiomyocytes  are  also  available  for  culturing  and  have  been  used  to  study  cardiac  
hypertrophy  [9].    
Limited  information  on  Galk  knock-­‐‑out  mice  is  available.    Two  isoforms  of  Galk  
are  present  in  mouse,  Galk1  and  Galk2.    The  Galk1  mouse  is  available  and  shows  
neurological  and  eye  phenotypes  related  to  galactokinase  deficiency  [237],  the  Galk2  
knock-­‐‑out  mouse  is  currently  available  through  the  International  Knock-­‐‑out  Mouse  
Consortium  (IKMC).    No  studies  have  been  performed  on  these  mice  so  far.    Examining  
the  effect  of  Galk1  or  Galk2  knock-­‐‑out  on  pressure  overload  or  calcineurin  
overexpression-­‐‑induced  hypertrophy  will  demonstrate  whether  our  discoveries  in  the  
fly  system  translate  to  the  mammalian  system.  
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